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ABSTRACT
RATIONALE: Long-acting slow effective release antiretroviral therapy (LASER ART) was
developed to improve patient regimen adherence, prevent new infections, and facilitate drug
delivery to human immunodeficiency virus cell and tissue reservoirs. However, maintenance of
sustained plasma drug levels, for weeks or months, after a single high-level dosing, could improve
regimen adherence but, at the same time, affect systemic toxicities. Of these, the most troubling are
those that affect the central nervous system (CNS) In an effort to facilitate LASER ART
development, “multimodal imaging theranostic nanoprobes” were created. These allow combined
bioimaging, drug pharmacokinetics and tissue biodistribution tests in animal models. Additionally,
dolutegravir (Tivicay, DTG), in both a native drug form and within a nanoformulations, were
administered to mice to investigate potential neurotoxicity or lack thereof in animal models for
further LASER ART technology development.
METHODS: Europium (Eu3+)- doped cobalt ferrite (CF) dolutegravir (DTG)- loaded (EuCF-DTG)
nanoparticles were synthesized then fully characterized based on their size, shape and stability.
These were then used as platforms for nanoformulated drug biodistribution. Rodents were
administered parenteral 45-mg/kg doses. DTG-associated changes in CNS homeostasis were
assessed by measuring brain metabolic activities. After antiretroviral treatment, brain subregions
were dissected and screened by mass spectrometry-based metabolomics.
RESULTS: Folic acid (FA) decoration of EuCF-DTG (FA-EuCF-DTG) nanoparticles facilitated
macrophage targeting and sped drug entry across cell barriers. Macrophage uptake was higher for
FA-EuCF-DTG than EuCF-DTG nanoparticles with relaxivities of r2 = 546 mM-1 s-1 and r2 = 564
mM-1 s-1 in saline, and r2 = 850 mM-1 s-1 and r2 = mM-1 s-1 in cells, respectively. The values were
ten or more times higher than what was observed for ultra-small superparamagnetic iron oxide
particles (r2 = 31.15 mM-1 s-1 in saline) using identical iron concentrations. Drug particles were
detected in macrophage Rab compartments by dual fluorescence labeling. Replicate particles

XVI
elicited sustained antiretroviral responses. After parenteral injection of FA-EuCF-DTG and EuCFDTG into rats and rhesus macaques, drug, iron and cobalt levels, measured by LC-MS/MS,
magnetic resonance imaging, and ICP-MS were coordinate. Within metabolomic experimentations,
metabolic drug-related dysregulation of energy and oxidative stress were readily observed within
the cerebellum and frontal cortex following native drug administrations. Each was associated with
alterations in neural homeostasis and depleted canonical oxidation protection pools that included
glutathione and ascorbic acid. Surprisingly, the oxidative stress-related metabolites were
completely attenuated when DTG was administered as nanoformulations. These data demonstrate
the importance of formulation design in control of DTG or perhaps other antiretroviral drugassociated CNS events.

16

CHAPTER 1
Introduction
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1.1 Global significance of HIV-1
Human Immunodeficiency Virus (HIV-1) is a progressive retrovirus of the human immune
system which, if left untreated, can eventually lead to acquired immunodeficiency syndrome
(AIDS). Causing a global pandemic shortly after its discovery in the early 1980’s, HIV-1 has been
in the crosshairs of medical research for several decades, with the molecular structure, function,
regulation, tropism, and means of viral persistence having now been documented [1-3]. Regardless
of such efforts, more than 70 million people have been infected with HIV-1 since its discovery,
with 35 million people succumbing to the virus after initial infection [4]. Additionally, it is
estimated that at the end of 2017 approximately 37 million people live infected with HIV-1 around
the world. Treatment and management of patients infected with the virus continues to be one of the
greatest challenges of the modern medical era.
Development of treatment options for patients infected with HIV-1 is arguably one of the
most significant victories in pharmaceutical research, with dozens of effective antiretroviral
therapies being brought to market since azidothymidine (AZT) was first approved in 1987 [5, 6].
Antiretroviral therapy (ART) has allowed for a completely new prognosis following HIV-1
infection; recently diagnosed patients no longer fear certain death within years but instead
anticipate a prolonged lifespan with a chronic but manageable disease. Furthermore, more recent
innovations in ART technology has allowed concurrent administration of multiple antiretroviral
compounds to patients, drastically increasing their effectiveness in limiting HIV-1 replication and
inhibiting viral resistance. Combination ART (cART) markedly reduces HIV-1 replication such
that HIV-1 RNA is undetectable within plasma, allowing for reduced disease morbidity [7, 8].
However, despite such pharmacological advances and sustained viral suppression, ART cannot
eliminate viral infection. Complete viral eradication requires the development of new and novel
drug technologies, with improvements in drug design and delivery being at the forefront of
significance
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1.2 HIV-1 virology and pathology
HIV-1 is a retrovirus, using its own reverse transcriptase to transcribe a single stranded
viral RNA into a double stranded DNA for integration into the host genome and completion of the
viral life cycle. Two identical copies of single stranded RNA reside within the cylindrical capsid
of the virus and contain genes needed for the encoding the structural viral proteins [1, 9]. Groupspecific antigen, or gag, encodes the proteins of the viral core and matrix, such as viral capsid
protein HIV-1 p24 and matrix protein HIV-1p17 [10]. The env gene encodes proteins that form the
viral envelope, specifically glycoprotein 120 (HIV-1gp120) and transmembrane glycoprotein 41
(HIV-1gp41). The pol gene encodes a variety of HIV-1 enzymes, such as reverse transcriptase that
is required for the transcription of HIV-1 RNA into DNA for integration into the host cell genome
[11]. All three genes are critical for the propagation of HIV-1 within an infected host, and as such
these genes and the proteins they encode have become biological targets of antiretroviral drug
(ARV) therapy.
Protease, ribonuclease, and integrase are also enzymes residing within the HIV-1 core
encoded by pol that are necessary for HIV-1 replication [12, 13]. In addition to these enzymes,
several accessory and immune-regulatory genes within the viral capsid core play a vital role for
viral function. Trans-activator of transcription, or Tat, causes substantially increased levels of
reverse transcription to occur after a small number of RNA transcripts are made via a positive
feedback loop [10]. Regulator of viral protein expression, or Rev, dictates the movement of RNA
from cytoplasm to nucleus. Other necessary proteins include viral protein R (Vpr), viral infectivity
factor (Vif), negative regulatory factor (Nef), and HIV-1p7 [14]. While the biological mechanism
in which Vpr, Vif, and Nef influence HIV-1 replication are not completely known, it has been
established that these proteins positively affect HIV-1 replication.
The primary target of progeny infectious HIV-1 and the most commonly infected cell is
the CD4+ T lymphocyte [15, 16]. This was shown by isolation, propagation and molecular analyses
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of the viral genome in HIV-1 infected patients [17, 18]. These investigations definitively showed
that proviral DNA is integrated within CD4+ T cells and to more limited degree monocytemacrophages [19]. Indeed, impaired immune response is characteristic of all stages of the disease
with parallel deficits in numbers and function [20]. Infection of a CD4+ T cells begins when an
HIV-1 virion encounters its cluster designation 4 (CD4) receptor together with its co-receptor
molecule, the C-X-C chemokine receptor type 4 (CXCR4). Co-receptor use ensures viral cell entry.
Tight binding of HIV-1 gp120 to the CD4 molecule(s) on the surface of the host cell allows the
membranes of the virus and the host cell to fuse. The virion’s RNA, proteins, and enzymes are then
released into the cell following successful cellular fusion and digestion of the protective virion
capsid, with the envelope of HIV-1 remaining on the outer membrane of the cell.
Reverse transcription is completed by HIV-1 enzymes utilizing the infected host cell’s
deoxynucleotides. Viral DNA synthesis occurs concurrently with the degradation of the original
viral RNA, as the reverse transcriptase enzyme also has RNase activity. During each iteration of
RNA to DNA reverse transcription within a infected host cell, the probability of a random mutation
is relatively high due to reverse transcriptase’s relatively poor proof reading capabilities [21]. This
is what allows HIV-1 to develop viral mutations over time that potentially is beneficial to its
propagation within the host, such as developing ART resistance. Reverse transcription is performed
twice to produce a double stranded DNA molecule, after which there is binding to the viral integrase
enzyme. Integrase can then transport the double stranded viral DNA into the nucleus of the host
cell as well as creating a cut within the host cell genome for viral DNA integration [22].
DNA replication, RNA transcription, and protein translation occurring via host cell
machinery allows for the production of progeny HIV-1 that occurs after assembly of viral proteins
with subsequent transport to the host cell membrane for virion packaging. Assembly is controlled
primarily by Gag precursor molecules, Pr55 Gag and Pr160 GagPol [23]. The production of a
mature virus particle consists of encapsidation of the viral RNA, viral budding, release of the viral
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particles from the infected cells, and finally proteolytic processing of Pr160 and Pr55 during
maturation [23].
1.3 Viral transmission
Transmission occurs by separate routes (through contaminated needles, by transfusion of
blood and blood products, from mother to fetus and by receptive anal or vaginal intercourse) [24].
The actual process ensues through cells or by the virus itself. As per the latter, HIV-1 is released
to float freely within plasma until they come in contact and interact with a host cell suitable for
entrance and infection. “Cell-to-cell transmission” is the alternative mechanism for the progression
of HIV-1 infection, in which direct contact between an infected cell with an uninfected naïve cell
results in HIV-1 transmission. Cell-to-cell transmission occurs during the fusion of HIV-1 infected
cells with that of uninfected susceptible cells; the fusion process causes the viral components to be
deposited into the uninfected cell, subsequently causing multinucleated giant cells [25, 26].

1.4 Immune Response to HIV-1
AIDS occurs as a consequence of progressive viral infection and CD4+ T cell depletion.
It is classified as patients infected with HIV-1 that have CD4+ T cell counts below 200 per µl,
compromising cell-mediated immunity, or by opportunistic viral, fungal, parasitic and
mycobacterial infections that are strongly associated with advanced HIV-1 infection [14, 27].
Ultimately, patients succumb to HIV-1 not directly from the virus itself, but rather indirectly as
opportunistic infections take advantage of a weakened and dysfunctional immune system.
However, the progression of the HIV-1 disease state, from initial infection/transmission to
complete immune failure, is a process taking many years or even decades, and is characterized into
several distinct stages defined by the current immune response [28]. These four stages are: primary
infection, a clinically asymptotic period, symptomatic HIV-1 infection, and HIV-1 to AIDS
progression. Each infected individual varies in their respective length, severity, and symptoms of
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each stage; it is of importance to mention that patients consistently taking ARV medication
generally will not progress to the later stages of the disease [28].
Primary infection is the beginning of HIV-1 disease progression as the virus establishes
itself within the host body. This stage typically lasts only a few weeks after initial transmission.
Within the first 24 hours after infection, HIV-1 virions infect dendritic cells within the mucous
membrane; after about 5 days, these infected dendritic cells are recruited to lymph nodes and the
peripheral blood, where replication rates dramatically increase. The primary infection stage is
characterized by substantially decreasing CD4+ T cells and exponentially increasing levels of
viremia, often millions of virus copies per milliliter of plasma [29]. Such a large number of HIV-1
viral particles within the blood allows for systemic infection of peripheral lymphoid organs.
Regardless of this viral spike, the body’s immune response during primary infection eventually
results in reduction of virus levels within the peripheral blood. Virus specific cytolytic T
lymphocytes (CTLs) appear early in infection and potentially downregulate HIV-1 replication [30,
31]. CD8+ T cells are also credited in controlling the initial viremia peak that is characteristic of
primary infection; activated and mature CD8+ T cells possess different anti-HIV-1 processes.
Specifically, CD8+ T-cells can release cytokines such as RANTES, MIP-1 alpha, and MIP-1 beta
that can effectively block the entry of HIV-1 into host cells by competing for or downregulating
cellular co-receptor CCR5 [30, 31]. Following a severe reduction in plasma viremia and a small
rebound in CD4+ T-cell populations, patients progress to the clinically asymptomatic stage.
The period of time between the initial primary infection stage and the development of
AIDS is classified as the clinically asymptomatic stage. After the initial viremia peak and
subsequent decrease in HIV-1 plasma characteristic of the primary infection stage, HIV-1 continues
to replicate within infected cells and is readily detected in almost all lymphoid tissue [32, 33].
Consistent viral replication results in chronic immune stimulation; this strain on the immune system
is thought to be responsible for its eventual deterioration as well as the progressive death of
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lymphoid tissue [34]. Despite continual propagation of the virus and gradually decreasing CD4+
T-cell populations, infected patients generally don’t exhibit any clinical symptoms at this stage, as
immunodeficiency has not progressed enough to compromise cell-mediated immune function.
The final phase includes both the stage of symptomatic HIV-1 infection as well as the
progression of HIV-1 to AIDS. While the immunological hallmark of the progression from the
asymptomatic stage was gradual loss of CD4+ T-cells, the symptomatic stage is defined by a
steeper decline in CD4+ T cell populations and overall increase in systemic viral load [35]. This is
due to systemic viral replication at multiple sites in addition to the high amount of replication
happening within lymphoid tissue. The amount of time required for the development of clinical
immunodeficiency from the asymptomatic stage is variable among infected individuals: indeed, the
complexity of host and viral factor interactions are integral to the eventually outcome of the disease
[28]. Overall, low amounts of viral replication and retention of immune function favors a slow
progression of HIV-1 infection, while high viremia and immune dysfunction leads to a more rapid
disease progression.

1.5 Antiretroviral therapy (ART)
The natural history of HIV-1 infection that is outlined in the previous section is dependent
on infected individuals not being administered any HIV-1 specific treatment during their infection.
This is representative of the clinical landscape in the decade following the discovery of HIV-1 in
1983, in which medical professionals were largely ignorant about the virus and its pathology.
Treatment options were limited if not non-existent during this period; testing positive for HIV-1
was universally fatal, with survival time directly dependent on the individual’s own progression
from initial infection to AIDS.
This changed in 1987 with the development and testing of a dideoxynucleoside reverse
transcriptase inhibitor (NRTI), azidothymidine (AZT), the world’s first antiretroviral drug used to
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treat HIV-1 [6]. Benefits of AZT treatment were limited; greater survival times were found in
patients at 24 weeks, but this effect was short-lived and by 48 weeks’ time, survival benefits were
no longer observed [36, 37]. Additionally, AZT treatment showed side effects of transient anemia
and malaise due to off target toxicities, particularly in high doses given to HIV-1 patients shortly
after approval. Regardless of AZT’s limitations, the effects seen on the survivability of HIV-1
patients spurred medical research to investigate the potential of antiretroviral therapy. Three
additional NRTIs were then released in quick succession: zalcitabine (ddC), didanosine (ddI), and
stavudine (d4T). All three medications had particular toxicities and as of present none are widely
administered within the clinic [38, 39]. However, the development and administration of these early
antiretroviral drugs, and their associated toxicities, inevitably led physicians to give treatment
sequentially or to alternate between different therapies, a strategy that would serendipitously prove
effective as more antiretrovirals became developed [40]. Patients continued to fare poorly within
the clinic, but with small reductions in the rate of adverse reactions there was optimism
antiretroviral research was heading in the right direction.
Combination NRTI therapy, in which two or more antiretrovirals are given as a treatment
concurrently, was another clinical concept that showed encouraging results in the early 1990s. The
development of lamivudine (3TC), a cytidine analog, allowed for another drug to be used in
combination with other NRTIs and proved to be synergistic with the other compounds [41]. But
despite such progressions, the quality of life for HIV-1 patients continued to be poor. Triple drug
combination strategies were the only cases showing any sign of significantly controlling HIV-1
infection, and early NRTIs, particularly thymidine analogs, continued to have issues with toxicity
[39].
The development of different classes of ARVs was perhaps the most substantial
advancement of HIV-1 therapeutics. Groups of drugs that have a direct effect on HIV-1 viremia
but do so via different biological mechanisms; when given in combination, have proved effective
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at limiting viral resistance while decreasing viral plasma levels. Saquinavir became the first
protease inhibitor (PI) approved in 1995, but initial formulations struggled with poor bioavailability
and deactivation by enzymatic metabolization [39]. Ritonavir, another PI, was developed shortly
after saquinavir. Ritonavir was found to be a potent inhibitor of one of the enzymes responsible for
deactivating saquinavir, and when given in combination, dual saquinavir and ritonavir
administration was found to be quite effective at HIV-1 suppression, though tolerability was low
[42]. Eventually is was determined that high-dose saquinavir and low-dose ritonavir

in

combination was optimal for effective protease inhibition, and still represents the recommended
usage for protease inhibition in the clinic at present [39]. Nevirapine became the first nonnucleoside reverse transcriptase inhibitor (NNRTI) approved in 1996, and it was found that if given
as a monotherapy that resistance develops relatively quickly. But with nevirapine given as part of
three-drug regimen, in which two NRTIs are also administered, HIV-1 was found to be nearly
completely suppressed and proved superior to dual therapy NRTI control groups in the Italy,
Netherlands, Canada, Australia Study (INCA Study) [43].
Different classes of ARV medications, which in turn could be given to patients in a variety
of different combinations, ultimately proved the key in defeating HIV-1 conferred drug resistance.
Such drug regimens become referred to as “highly active antiretroviral therapy” (HAART) and
truly marked a turning point in the battle against the HIV-1 pandemic. A substantial decrease in
HIV-1 associated morbidity and mortality associated with HAART administration changed the
world: the leading cause of death among young people within developed countries had become
augmented to a chronic but manageable affliction [44]. Perpetual variety in HAART treatment not
only prevents HIV-1 for developing resistance to specific ARVs but also prevents HIV-1
replication to the point where plasma viral levels are undetectable [45]. To date, there are five
different classes of antiretroviral medications: NRTIs, NNRTIs, PIs, entry/fusion inhibitors, and
integrase inhibitors.
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•

NRTIs work to inhibit the enzyme responsible for the transcription of the viral
RNA into DNA for integration. This is accomplished by NRTIs being nucleoside
analogs; they compete with natural deoxynucleotides within the cell for
incorporation into the growing DNA strand during reverse transcription. Such
analogs lack the 3’ OH group needed to successful chain elongation. When the
next deoxynucleotide is incorporated into the growing DNA chain, the 5’ to 3’
phosphodiester bond needed for continuation cannot be formed. Failure to form
this bond halts the process, effectively preventing viral RNA from being reverse
transcribed. Currently approved NRTIs used in treatment of HIV-1 include:
Zidovudine, Didanosine, Zalcitabine, Stavudine, Lamivudine, Abacavir, and
Tenofovir. It should be noted that Tenofovir is a unique type of NRTIs and is more
accurately described as a nucleotide reverse transcriptase inhibitor (NtRTIs).
Nucleoside analogs normally undergo phosphorylation to be converted into
nucleotides, which become active for incorporation. Tenofovir is administered as
an already chemically active nucleotide analog, with no need for activation via
phosphorylation

•

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) again inhibit the
transcription of viral RNA into DNA but do so by more direct means. NNRTIs
non-competitively bind to an allosteric site on reverse transcriptase, resulting in a
confirmation change and inactivation of the enzyme. If given as a monotherapy,
HIV-1 resistance to NNRTIs can be established fairly quickly due to mutations in
reverse transcriptase during continual iterations of replication; mutations in which
NNRTIs cannot bind to the RT allosteric site are positively selected for (REF).
Because of this, NNRTIs are commonly given in conjunction with one or two other
NRTIs. Currently approved NNRTIs include: Nevirapine, Delavirdine, Efavirenz,
Emtricitabine, Etravirine, and Rilpivirine.
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•

PIs effectively prevent the maturation and release of newly synthesized viral
proteins by inhibiting the enzyme needed for their cleavage and subsequent
activation. As described above, once viral RNA has been reverse transcribed into
DNA and integrated into the host genome, viral proteins are transcribed by host
cell machinery to produce new viral particles. Newly synthesized viral proteins
must become cleaved by the viral protease to become fully activated and
infectious. PIs bind to the active site of viral proteases, preventing them from
having enzymatic activity and inhibiting the completion of HIV-1 life cycle.
Currently approved PIs include: Saquinavir, Ritonavir, Nelfinavir, Amprenavir,
Lopinavir, Atazanavir, Fosamprenavir, Tipranavir, and Darunavir.

•

Entry and fusion inhibitors are a relatively new class of ARV drugs with only 2
compounds currently being approved for HIV-1 treatment: Enfuvirtide, approved
in 2003, and Maraviroc, approved in 2007. For entrance of HIV-1 into a host cell,
viral envelope surface glycoproteins must interact with membrane surface
receptors. HIV-1 envelope glycoproteins are normally a heterotrimer consisting of
three molecules of gp120 and three molecules of gp41. Binding of viral gp120 to
the CD4 receptor of a host cell causes a conformational change in the glycoprotein,
allowing interaction with host cell co-receptors CCR5 or CXCR4. Co-receptor
binding ultimately allows fusion between the host cell membrane and portions of
gp41 within viral envelope. Enfuvirtide prevents this fusion event by changing the
N-terminal heptad repeat of gp41 to an inactive hetero six helix bundle, preventing
it’s fusion interaction with the host cell membrane. Maraviroc utilizes an
interaction with co-receptor CCR5, binding to it and preventing association with
gp41, effectively inhibiting entry into cells with the CCR5 co-receptor.

•

Integrase inhibitors were developed to block the enzyme responsible for the
integration of newly synthesized HIV-1 DNA into the host cell genome. Integrase
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catalyzes two reactions within the HIV-1 replication life cycle. The first is 3’ end
processing in which two nucleotides are removed from one or both of the 3’ ends
of the viral DNA, while the second is the “stand transfer reaction” in which the
processed 3’ ends are covalently bound to host chromosomal DNA. Inhibition of
integrase prevents these steps from occurring, effectively preventing the infection
of the host cell. Currently approved integrase inhibitors are: Raltegravir,
Dolutegravir, Elvitegravir, and Bictegravir.
Despite such significant advancements in the development of HIV-1 treatment options,
HIV-1 persists and remains yet to be completely eradicated. Thought HAART can reduce plasma
viral levels to undetectable levels and allow patients to live decades after their initial infection and
diagnosis, HIV-1 continues to persist throughout the world.

1.6 HIV-1 reservoirs
HIV-1-infected individuals receiving clinically effective ART must remain on such therapy
continuously and uninterrupted for the entirety of their lives, despite the effectiveness of such drug
regimens as described above. This can primarily be attributed to the ability of HIV-1 to escape
immune surveillance and persist within latently infected immune cells in cellular and anatomical
locations termed “HIV-1 reservoirs” [46]. Such reservoirs were discovered in the mid 1990’s
during the development of HAART, in which reports exhibited HIV-1 provirus residing within
latently infected resting life-long memory CD4+ T lymphocytes [47]. Such cells have HIV-1 DNA
integrated within their genome but are not actively producing new virions; rather they are in a latent
resting state until they become activated weeks, months, or sometimes years after they initially
become infected. Such latency renders the majority of current ARV therapy ineffective; inhibiting
steps of viral replication has little consequence on cells that are not actively producing new virions.
Indeed, HIV-1 patients who interrupt continuous ART display rapid viral plasma rebound even if
plasma levels had been suppressed to undetectable levels for years [48]. Furthermore, such latently
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infected immune cells often reside in anatomical locations that ARV therapy poorly penetrates,
allowing for potentially high levels of replication within HIV-1 reservoirs [49]. Such latently
infected and long lasting groups of immune cells can be categorized based on a commonality
between the types cells they reside in, or the anatomical location large amounts of such cells accrue.
Different mechanisms have been proposed for the persistence and maintenance of HIV-1
cellular reservoirs. These include inadequate penetration of ARV drugs into tissues sites of active
replication, replenishment of infected cells via residual viral replication, intrinsic stability of
latently infected and resting CD4+ T-cells, and periodic homeostatic proliferation of cells in
sanctuary sites located within various tissues compartments [50-53]. Overall, HIV-1 persists
primarily within immune cells of two broad categories: CD4+ T-lymphocytes of a variety of
functions including central memory, effector memory, transitional memory, and naïve CD4+ Tcells, as well as monocyte-derived macrophages. Anatomical locations of HIV-1 sanctuaries are
also numerous and diverse, with HIV-1 persistence and replication being found in peripheral blood,
peripheral lymphoid tissue, gut-associated lymphoid tissue, the reticuloendothelial system (RES),
and the central nervous system (CNS).
1.6.1 Peripheral lymphoid tissue
Lymph nodes are a primary site for viral replication of HIV-1, with large amounts of
infected cells and free virions being contained within the follicular dendritic cell network [29, 52].
HAART is effective in reducing HIV-1 RNA levels within lymph nodes, with a clearance half-life
only marginally longer than that found in blood [54, 55]. However, both HIV-1 RNA and DNA
can be detected within lymph nodes following years of viral suppression due to various
combinational ART [56]. A multitude of different studies involving ART-treated SIV-infected
rhesus macaques found that HIV-1 RNA and/or DNA levels are highest within the lymph nodes
compared to other sanctuary sites such as plasma or the gut, with several of these studies finding
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an association between high levels of viremia and low ARV concentrations within such peripheral
lymphoid tissues [57-59].
1.6.2 Gastrointestinal tract and GALT
Following transmission of HIV-1, the gastrointestinal tract is one of the earliest targets of
HIV-1 infection and is one of the tissues with the highest number of infected cells. This is primarily
due to the gut containing a large portion of the lymphoid tissue and lymphocytes within the body
[60, 61]. In vitro studies of isolated primary gut mucosal CD4+ T-cells not only show an increased
susceptibility to HIV-1 infection but also support increased levels of viral replication [62, 63]. Such
findings are attributed to these cells having increased T-cell activation and greater levels of CCR5
expression [64]. Clinical investigations of HIV-1 RNA and DNA levels within rectal biopsies
showed the viremia remained stable over 1 year of ART, with gut HIV-1 DNA+ cells being twice
that in blood [65]. Additional studies report HIV-1 DNA levels per million CD4+ T-cells were 56 times higher within the ileum compared with blood in patients that had been taking ART for up
to 10 years [66]. Averaging the level of HIV-1 DNA across 4 separate gut sites, it was estimated
that the gut harbors 83-95% of all HIV-1 infected cells within the body [67]. Again, such
phenomena can be attributed both to the gut intrinsically having large amount of lymphocytes as
well as poor penetration of certain ARVs into the gut.
1.6.3 Reticuloendothelial system
The reticuloendothelial system is also referred to as the mononuclear phagocyte system
and consists primarily of monocyte and macrophage cells. While the RES encompasses multiple
different immune cells within different tissue sites, for the purpose of this dissertation focus will
be put on monocytes of bone marrow and peripheral blood, residual macrophages of the spleen,
and Kupffer cells of the liver, as these are the areas of biological interest that are targeted in chapter
2 and chapter 3. Circulating monocytes terminally differentiate into mononuclear phagocytes (MP)
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and, once associated with a particular tissue, no longer replicate [68]. The utility of MPs is primarily
that of phagocytosis, in which cells engulf cellular debris and/pathogens and become antigen
presenting cells (APC). While the percentage of MP cells that become infected with HIV-1 is quite
low in comparison with that of CD4+ cells, the biological consequences of such infection are drastic
[69]. Additional utility of MPs consist of the ability to infiltrate a large variety of different tissue
sites: such cells containing HIV-1 would have a “trojan-horse effect” as they would carry HIV-1
into anatomical sites that free virions or even infected CD4+ T-cells would not be able to access,
particularly the brain as discussed below. Therefore, infected MPs are significant contributors in
the establishment of HIV-1 reservoirs. However, the migratory behavior of MPs, coupled with
their large intracellular compartments, make them ideal targets in the establishment of drug depots,
as discussed in later chapters. Multiple studies have confirmed that presence of infected Kupffer
cells within the liver as well as the presence of infected red pulp macrophages within the spleen,
with one study finding evidence of compartmentalization between the plasma and the spleen [70,
71].

1.7 Central nervous system as a major reservoir1
Of all the complications of HIV-1, the most foreboding and chronic issue is the disease’s
effects on the nervous system. Soon after the discovery and description of AIDS, neurological
impairments were described and associated with advanced disease and profound immune
suppression [72, 73]. These aggravations can often become severe with a triad of cognitive, motor,
and behavioral disturbances [74-79]. Whether directly caused by the virus or indirectly misfolded
and aggregated proteins, all of the processes discussed underlie the tempo and progression of
disease [80-86]. A significant body of data has emerged in the past twenty five years on how HIV1 affects the brain and causes progressive clinical impairment [72-74, 87-89]. Particular focus will
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be given here on how HIV-1 can pass the blood brain barrier (BBB) into the brain and the cellular
targets of HIV-1 after entering the brain parenchyma.
1.7.1 Entry into the brain
HIV-1 is thought to gain entry to the protected environment of the CNS via a variety of
different routes, and it is likely that HIV-1 invasion into the brain is achieved by utilizing more
than one path [90-92]. Several mechanisms have been proposed by which HIV-1 gains entry into
the brain [93]. In the most prominent and well supported theory, HIV-1 enters the brain inside
infected macrophages, migrating into the brain parenchyma through BBB disruption and
establishment of a chemokine gradient. This model is commonly referred to as the “Trojan horse
hypothesis,” as HIV-1 buds into intracytoplasmic vesicles in macrophages with limited expression
of viral proteins on the cell surface, allowing for escape from immune surveillance [94, 95]. An
alternative theory is that cell-free HIV-1 virus directly infects the endothelial cells and astrocytes
of the BBB, however, this model is partially flawed as there is low or nonproductive infection of
cells of the BBB [96]. In another model, the transcytosis model, HIV-1 invades the CNS through
internalization of the virion by endothelial cells or by astrocyte foot processes by macropinocytosis
or endosomes, with subsequent transfer of the virus to CNS cells [97]. In the brain, monocytederived perivascular macrophages are the main cell type infected by HIV-1, with limited expression
in microglia and restrictive/non-productive replication within astrocytes [20, 98, 99]. The virus
replicates within the infected macrophages and can infect other CNS cells, particularly other
macrophages that perpetuate the infection within the CNS. Astrocytes and capillary endothelial
cells have been found to contain HIV-1 protein and DNA in infected individuals [20]. Depending
on the number of infected brain macrophages, the extent of CNS inflammation, and the number of
recruited monocyte-derived macrophages, the course and extent of neurological impairment can be
tentatively predicted.
It has been suggested that the early CNS HIV-1 infection has the possibility of inducing
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immune activation of the brain parenchyma, resulting in a subsequent increase in the number of
microglial cells, up-regulation of MHC class II expression, and local production of cytokines. In
the normal CNS, neurons, oligodendrocytes, astrocytes, and microlgia are intimately associated
with each other and communicate through specialized synapses and cell junctions; this direct cell
contact is required for proper glia maturation and function [100-102]. For glia to undergo
transformation to an activated amoeboid phenotype, they need to be freed from inhibitory neural
and astrocytic responses [25]. Activated microglia and, to a lesser extent, astrocytes express MHC
class I and II antigens and adhesion molecules and secrete cytokines and reactive oxygen
intermediates, and all have been shown to be important factors contributing to HAD [25, 103, 104].
Microglia and astrocytes produce chemokines and control monocyte migration across the BBB
[105-109]. The event(s) triggering monocyte invasion into the nervous system likely involves the
secretion of macrophage attractant chemokines and the up-regulation of adhesion molecules on
activated endothelial and immune cells. Proinflammatory factors induce cytokines and chemokines
(such as IL-8, IFN-γ, IP-10, growth-related oncogene α [GRO-α], MIP-1a, MIP-1b, RANTES, and
MCP-1) found in infected brain tissue and may also participate directly in the disease process. Both
cytokines and HIV-1 Tat induce expression of E-selectin on BMVEC. The likelihood of this event
is increased by the release of nitric oxide (NO). TNF-α and Il-1β also induce expression of VCAM1 on the BMVEC [110]. This induction of adhesion molecules allows binding of HIV-1-infected
cells to the brain endothelium. Virus and activated macrophage entry into the brain is likely
precipitated by BBB damage heralded by activation of brain MP. Neuronal damage and alterations
in the integrity of tight junction and/or regulation of its immune function occur as consequences of
viral and cellular secretory products and are crucial to HIV-1 brain transport [109].
The BBB consists of a monolayer of specialized, non-fenestrated, microvascular
endothelial cells. Associated with the BBB is a capillary basement membrane on the abluminal side
of the monolayer, with tight junctions connecting the BMVEC and no transcellular pores [111].
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These together serve to restrict movement of cells and macromolecules, including viral particles,
throughout much of HIV-1 infection. Nonetheless, a number of biological situations enable the
aberrant trafficking of cells across the BBB as a result of HIV-1 infection, allowing for the virus to
enter the brain. The movement of viral particles from the periphery into the brain is facilitated
through immune and structural BBB compromise. This process occurs late in the course of disease
and serves to speed the overall pathogenic process of the disease. HIV-1 infection alters the BBB
itself; numerous functional and structural abnormalities are of consequence, including damage to
the basement membrane, damage to tight junction proteins, morphological and functional
alterations of the BMVEC, and subsequent protein leakage [112-117]. As a result, HIV-1-infected
monocytes and/or CD4+ T lymphocytes as well as cell-free virus are able to cross the BBB [114,
118].
Inflammation also serves to enhance trafficking of cells across the BBB. ICAM-1, VCAM1, and E-selectin are up-regulated on the surface of BMVEC and astrocytes after exposure to
proinflammatory factors secreted from microglia and astrocytes and/or activated leukocytes from
the periphery; these serve to augment the process of adhesion molecule expression on not only
BMVEC but astrocytes as well [106, 119]. Late in the disease process, inflammatory cytokines are
produced at high levels and allow the BBB to be more easily breached. These proinflammatory
cytokines induce a transient increase in endothelial permeability by increasing secretion of
endothelial vasoactive factors, such as NO [120]. TNF-α and IL-1β increase the production of other
inflammatory mediators, including arachidonic acid–derived PAF [106, 107, 121]. These serve to
promote monocyte migration across the BBB and ultimately into the brain parenchyma. The
adhesion molecules ICAM-1 and VCAM-1 on the luminal surface of the BMVEC bind LFA-1 and
Vl-4 on the monocyte, resulting in migration of the monocyte between the endothelial cells during
the early stages of viral infection.
Changes in cellular physiology that are induced as a consequence of inflammation also
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influence transmigration of inflammatory cells into the CNS. Chemokines are secreted at sites of
inflammation in all tissues and work to guide leukocytes in a concentration-dependent manner[122124]. Importantly, specific chemokines will attract specific populations of leukocytes. MIP-1α and
MCP-1 levels are increased during HIV-1 encephalitis and are potent chemoattractants for
macrophages as well as CD4+ T lymphocytes [121, 125]. Increasing damage to the BBB impairs
its ability to protect the CNS from the periphery resulting in cells and toxins being able to reach the
CNS unchecked. Levels of inflammatory factors greatly increase and lead to a cascade of events
culminating in further BBB dysfunction. These processes, taken together, affect MP-induced
neuronal destruction during HAD.
The Trojan horse hypothesis is based on the concept that infected monocytes and
lymphocytes act as cellular vehicles that can transport HIV-1 across the BBB, crossing from the
periphery to the CNS. The specific mechanism of this process has not been completely elucidated,
however, observations as well as a substantial body of scientific data support this claim. Monocytes
and CD4+ lymphocytes the primary target of HIV-1 infection outside of the CNS, and analysis of
HIV-1 infected brains have found large accumulations of HIV-1 infected macrophages within
neuronal tissue [126-128]. Expression of adhesion molecules as well as chemo attractants within
the CNS is higher in individuals experiencing HIV-1 dementia, allowing increased interactions
between infected leukocytes and brain endothelium plus increased recruitment of these monocytes
for transmigration [129].
These observations converge into the idea of a “snowball” like effect, in which initial HIV1 invasion occurs in very small amounts, with increasing levels of invasion facilitated by signaling
initiated by the resulting microenvironment of the initial migrating infected cells. Indeed, several
groups have reported findings supporting this claim. HIV-1 infection of human peripheral blood
monocytes resulted in higher expression levels of LFA-1, and factors released by these infected
cells induce expression of adhesion molecules E-selectin and VCAM by endothelial cells [96, 112,
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130]. Upon immunohistochemical analysis of HIV-1 infected brain tissue, E-selectin levels were
substantially increased in HIV-1-demented individuals as compared to non-demented patient’s
brain samples [115, 117].
Chemokines play a vital role in the transmigration process, and studies have reported
aberrant expression levels of both chemokines and their respective cell surface receptors in HIV-1
infected leukocytes [101, 123]. Monocyte chemotactic protein 1, or MCP-1 (also referred to ass
CCL2) has long been established as a principal attractant for monocytes and activated t-cells, and
studies have indicated that it is integral for monocyte transmigration into the brain parenchyma
[131]. Analysis of CSF from HIV-1 infected patients exhibiting dementia found elevated levels of
MCP-1 [132, 133]. These findings, taken together, indicate that adhesion molecules and
chemokines likely play an important role in facilitating leukocyte transmigration and subsequent
invasion of HIV-1 into the CNS.
Although the major targets of HIV-1 in the brain are macrophages and microglia, there
have been some reports of other cells of the brain being infected by HIV-1, including the endothelial
cells of the BBB [134, 135]. This highlights another theory of HIV-1 entry into the CNS; direct
infection of perivascular endothelial cells and astrocytes within the blood brain barrier. The support
for this hypothesis is weak, and suggests that this route of viral entry occurs only in small amounts,
most likely in conjunction with the other entry mechanisms discussed. Groups have reported that
in HIV-1 infected patients, brain microvascular endothelial cells (BMVECs) have exhibited
dysfunction and rampant apoptosis [136, 137]. Astrocyte viral infection is very low and often
results in minimal reproduction of the virus, however, several studies have demonstrated that
astrocytes that do become infected increase toxicity and inflammation surrounding CNS cells, thus
propagating HAND pathology [129]. It is also possible that infection of astrocytes occurs only the
late stages of the disease, long after the initial invasion of the virus, as one study concluded that up
to 19% of astrocytes were infected with in patients exhibiting dementia; this same study also found
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correlation between areas of HIV-1 infected astrocytes and increased rate of macrophage/monocyte
transmigration [134]. Based on these findings, it is unlikely that direct infection of endothelial cells
and astrocytes is the main mode of HIV-1 entry into the CNS. However, it is plausible that these
cells, once infected, can participate in subsequent infection of other cells in the CNS and lend a
hand in the creation of a viral reservoir.
Another possibility of HIV-1 invasion into the CNS is that transcytosis, in which
endothelial cells or astrocytes absorb the HIV-1 virion via macropinocytosis or endosomes and
mediate transfer to CNS cells. While the basic idea of this hypothesis is supported with compelling
data from multiple groups, the precise mechanism has yet to be determined and is entangled in
controversy within the scientific community [138, 139]. One group has reported the process being
pH independent and thus non-endosomal, while others have indicated for a pH dependent
mechanism [114, 140]. In vitro studies using electron microscopy have shown viral particles
localized within structures comparable with endosomes [114]. Increased surface microvilli of brain
endothelial cells and increases in numbers of cytoplasmic vesicles are indicative of
macropinocytosis, with both findings demonstrated experimentally in vitro [141]. While it is
evident that endothelial cells and astrocytes have the capability to acquire HIV-1 by transcytosis,
how these cells transfer and propogate infection of the virus to other cells within the CNS has yet
to be investingated.
1.7.2 HIV-1 targets within the CNS
1.7.2.1 Mononuclear phagocytes
The pathogenesis of HIV-1-associated CNS disease centers around mononuclear
phagocytes (MPs), which include blood borne macrophages, dendritic cells, tissue macrophages,
and microglia.. Macrophages are the principal cell infected in the brain and become activated and
recruited into tissue during inflammation and emigrate into the CNS during disease [128, 142].
This influx is usually transient, however, and will revert to a quiescent state after the inflammatory
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process has subsided. For HIV-1-encephalopathy and HIV-1 associated dementia (HAD), the
process never subsides, as brain inflammation is continuous and induced by ongoing viral
replication. Mononuclear macrophages are preferentially infected by HIV-1 due to their CD4
receptor and CXCR4 co-receptor; both of which help mediate the fusion of the HIV-1 envelope
with the host cell membrane. Subsequent activation and differentiation into macrophages further
increases the efficiency in which these cells replicate and spread the virus [126, 143]. Such cells,
once in the CNS, initiate a “pull” mechanism of activation and recruitment via chemotactic and
inflammatory signals such that more monocytes are attracted to the brain, increasing the amount of
HIV-1 as well as activating and infecting other cells within the CNS.
The perivascular macrophage is an actively studied MP cell type with involvement in HAD
pathogenesis. Normally these cells exist between the glia limitans and basement membrane of the
choroid plexus and CNS capillaries and are derived from circulating monocytes. Because of their
anatomical proximity to cerebral vessels in the brain, perivascular macrophages are likely
susceptible to HIV-1 that crosses the BBB [144]. .They are in close association with the bone
microvascular endothelial cells (BMVEC), and this collaboration allows them to serve as sentinels
for the CNS. In fact, perivascular macrophages act as intermediates between the peripheral
circulation and the microglia. Since microglia are in contact with these macrophages, signals may
be rapidly communicated deep into the CNS from interactions at the perivascular space.
Transmission of virus and/or inflammatory responses in the brain may occur between these
perivascular macrophages and glial cells [20, 128, 145].
Parenchymal microglia occur in significant numbers in the CNS and may constitute up to
10% of CNS cells. These cells enter the CNS during gestation and have a very low turnover rate
[100, 128], in contrast to perivascular macrophages, which are continuously replenished from the
bone marrow. Parenchymal microglia act as the resident macrophages within the brain and are
responsible for the primary immune response within the brain. Normally, parenchymal microglia
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and macrophages in the CNS are easily distinguished from each other by morphology, but
activation of microglia results in them displaying macrophage-like properties [146]. There are two
morphological subtypes of microglia. The first, ramified microglia, are resting cells with reduced
secretory and phagocytic activity making up the web of microglia that span the CNS [146, 147]. In
contrast to perivascular macrophages, they have weak antigen-presenting capability. The second
morphological subtype, amoeboid in form, is a morphological intermediate and transitional cell
between the ramified microglia and the brain macrophages [146]. This subtype is not found in the
normal adult CNS but rather in inflammatory and demyelinating conditions.
Infection of brain MPs eventually leads to the formation of multinucleated giant cells
(MGC). These cells result from the fusion of HIV-1-infected brain MP with uninfected monocytederived macrophages (MDM) or microglia [99, 128, 148]. This fusion is mediated by HIV-1envelope glycoproteins present at the surface of infected cells with CD4 and chemokine receptors
at the surface of uninfected cells [15, 149-151]. The MGCs are large, irregularly round, elongated
or polyhedral, with dense eosinophilic cytoplasm in the center and vacuolated at the periphery
[148]. MGC formation is found throughout the brain in HIV-1 disease, but is characteristically seen
primarily in the deep brain structures and most commonly in subcortical white matter. Although
pathognomonic of HAD, giant cells are only found in 50% of patients [25, 26, 152].
1.7.2.2 Astrocytes
Astrocytes are critical for the survival of neurons and their function may be impaired in the
context of HIV-1 infection. Astrocytes are responsible for maintaining homeostasis in the CNS and
are important in the detoxification of excess excitatory amino acids such as extracellular glutamate
levels [153, 154]. However, infected astrocytes can produce cellular factors that may adversely
affect neuronal survival [121, 155, 156]. Astrocytes play a dual role in the pathogenesis of HIV-1related encephalopathy; in HIV-1 infection, astrocyte glutamate reuptake is impaired, possibly due
to interactions with infected macrophages. However, glutamate release in astrocytes is also induced
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by activated macrophages [157]. Activation of the CXCR4 receptor by stromal cell-derived factor
1 (SDF-1) results in the release of extracellular TNF-α and downstream release of glutamate [157].
During HIV-1 infection there is an amplification or regulation of neurotoxic signals among
astrocytes and microglia. The HIV-1 protein Tat induces expression in astrocytes of MCP-1, a
chemoattractant for macrophages, and IL-8 and inducible protein-10 (IP-10), which attract multiple
leukocyte types [124, 132].
Astrocytes both proliferate and undergo apoptosis in HIV-1 CNS infection [154]. The level
of astrocyte apoptosis correlates strongly with both the severity and rate of progression of HIV-1
dementia. Direct infection of astrocytes by HIV-1 is minimal due to an absence of the CD4 receptor
[158]. Although studies have reported that infection of astrocytes can be both productive and
unproductive, recent studies have concluded that productive HIV-1 infection of astrocytes is
infinitesimally small, with .0025% of brain astrocytes undergoing productive infection [134, 158].
HIV-1 virus enters these astrocytes via endocytosis in which endosome internal machinery
degrades the majority of the viral particles; thusly HIV-1 astrocytic endocytosis is seen as a “kiss
of death”, as only a very small amount of viral particles survive and establish a productive infection
[158]. Unproductive infection of astrocytes occur more frequently, with groups reporting 3-19%
of astrocytes within infected brain tissue carrying HIV-1 DNA [134, 159].
1.7.2.3 T-cells
.

CD4+ T cells serve as important reservoirs of HIV-1, as a small proportion of these

cells harbor HIV-1 in a stable, inactive form. Normal immune processes can activate these
cells, resulting in the production of new HIV-1 virions. After transmigration through the
BBB, T cells are able to instigate cell-to-cell spread of HIV-1 through CD4-mediated
fusion of an infected cell with an uninfected cell. In addition, phagocytosis of CD4+ T cells
by MP can result in the spread of virus [160, 161]. Activated T cells penetrate the BBB
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after insult to the CNS and can initiate both protective and toxic inflammatory responses
[162]. Protective responses are elicited through elimination of the ongoing infectious agent
by innate, humoral, and cytotoxic immune activities. Nonetheless, widespread
inflammation in the setting of HIV-1 often leads to damage of the BBB and further
transendothelial migration of leukocytes entering the nervous system [109]. Inflammation
of the brain and spinal cord actively attracts T cells to the CNS. Macrophage inflammatory
protein-1 alpha (MIP-1α) and MIP-1β are relevant to the cellular recruitment and immune
activation during HIV-1 infection, as both use CCR5 as their receptor [122, 163-166]. MIP1α selectively attracts CD8+ and MIP-1β recruits CD4+ lymphocytes. Both MIP-1α and
MIP-1β are produced by HIV-1-infected monocytes and are closely linked to viral
replication [125].
During HIV-1 infection, more T cells are activated to a blast phase [167-169]. Once within
the CNS, the lymphoblasts search for antigen as they migrate through the parenchyma. Such cells
can easily encounter and engage perivascular macrophages through direct cell-to-cell contact or
through soluble factors released. CD4+ T lymphocytes are responsible for most of the HIV-1
replication in the periphery, and HIV-1 may enter the CNS in infected lymphocytes during the late
stage of the disease. As the T cells migrate through the parenchyma, they secrete the cytokines that
lead to activation of MP and an amplification of inflammatory cell responses throughout the CNS
region involved [170]. If these activated T cells are infected, they will shed virus as they migrate.
At the same time, they induce CD4 expression on cells susceptible to HIV-1 infection, rendering
them even more susceptible. T cells expressing the CD40 ligand (soluble and bound forms) can
activate both infected and noninfected monocytes that express TNF-α and CD40 receptors [167,
171, 172]. Macrophages become activated by way of scavenger receptors as they clear the debris
of dead virus-infected cells [12, 161]. Since viral replication occurs mostly within CD4+ T cells,
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direct cytopathic effects of HIV-1 may be attributed to cell death [173]. The decline in CD4+ T
lymphocytes allows macrophages, without control, to express a metabolically active, tissuedestructive phenotype.

1.8 ART associated neurotoxicity
While it is likely that HIV-1 invasion into the brain and a subsequent inflammatory cascade
is responsible for the development of adverse neuropsychiatric events in infected patients, other
potential mechanistic causes are certainly possible. Such reasoning is a result of the prevalence of
HAND remaining consistent in groups of infected individuals despite the introduction of HAART,
with 15-55% of HIV-1+ individuals estimated to have HAND, a proportion comparable to the precART era [89, 174]. It should be noted that more recent HAND cases in the era of HAART
represent more milder forms of the condition, however, additional studies have indicated that
HAND becomes more prevalent and severe as patients grow older [89, 174]. Additional risk factors
for the development of HAND include cardiovascular disease, age, co-infection of hepatitis C,
substance abuse, and concomitant psychiatric illnesses [175]. Therefore, it is likely that the onset
of neuropsychiatric complications is multifactorial, with many causes working in tandem to
propagate HAND in HIV-1 infected patients. A potential contributor to HAND pathology not yet
discussed is that of the antiretroviral medications themselves. Indeed, while the introduction of
cART has resulted in a marked reduction in morbidity and mortality in HIV-1 infected patients, the
off target effects can be quite substantial [176, 177].
Unfortunately, little information on the effects of antiretrovirals within the CNS is
available, with studies of off target neurotoxicity in ART cohorts being reported only within the
past decade [178]. This can partly be attributed to more recent ART development being focused on
drugs that can pass the BBB to readily control the HIV-1 CNS viral reservoir; increasing ARV
concentrations in the brain would result in decreased CNS viremia, subsequently leading to a
decrease in adverse neuropsychiatric events based on mechanisms described above. Based on
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previous observations of severe AIDS associated dementia seen in the pre ART era, it would seem
that decreased ARV brain concentrations causing less neuropsychiatric problems would be the
opposite expected effect.

However, one such study found exactly that. In a group of

immunologically and virologically suppressed patients, researchers found that patients reported
improved cognitive abilities for up to 96 weeks following election to cease treatment [179]. Such
findings were opposite of the groups expected hypothesis and raised the possibility that low ARV
concentrations within the brain, while effectively reducing brain viremia, can have some
detrimental effects.
The NNRTI Efavirenz has long been considered an excellent antiretroviral particularly
when

used

in

combination,

such

as

Combivir

(lamivudine/zidovudine),

Kivexa

(abacavir/lamivudine), and Truvada (tenofovir/emtricitabine) [180]. While these therapies are
extremely effective at systemically reducing viral load, the most consistently reported side effect
of efavirenz is neurotoxicity, with one study reporting 40-60% of patients on efavirenz having CNS
toxicity, and 25-40% exhibiting psychiatric effects [181]. In multiple studies the number of CNS
effects attributable efavirenz is almost double that of other antiretrovirals it was compared to [182184]. These off-target toxicities within the CNS contribute to a higher numbers of discontinuation
of therapy compared to newer, less toxic drugs, further compounding problems with HIV ART
compliance.
Additional studies investigating ARV neurotoxicity have found that a variety of
antiretrovirals have exhibited toxic effects on neurons; however, such studies were performed on
in vitro neuronal cultures and as such conclusions are limited. Highest neurotoxicity within neurons
was seen in abacavir, efavarenz, etravirine, nevaripine, and atazanavir, with some toxic
concentrations overlapping drug levels clinically found within the CNS of patients [178]. In
general, clinically relevant concentrations showed modest levels of toxicity. Nonetheless, such
findings indicate the need for careful studies of the effects of ARV compounds at concentrations
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required to suppress viral replication and to guide the use of compounds that will minimize CNS
complications.
Dolutegravir, a potent integrase strand inhibitor, is one of the more recent ARV drugs to
come to market with its medical use being approved in 2013. DTG readily crosses the BBB and
has been found to accumulate within CNS tissues. Additionally, some of the more commonly
reported side effects of DTG administration is that of headache and insomnia. Though these off
target effects are minor and generally well tolerated, they still raise concern of DTGs contribution
to adverse neuropsychiatric events in HIV-1 patients. Furthermore, a recent study following DTG
administration to women at the time of conception exhibited a potential increased risk for neural
tube defects in their newborns [185].

1.9 Theranostics
Over recent decades, nanotechnology has garnered a considerable amount of interest
within the scientific community, with medical research being no exception. Indeed, the ability to
reliably and consistently produce materials with dimensions and tolerances of less than 100
nanometers (nm) has proven extremely useful across a diverse multitude of research fields. The
impact nanotechnology has had on medicine, both in research laboratories and within the clinical
landscape, cannot be understated. Constant innovation in the synthesis and characterization of
nanoscale materials has resulted in products with high amounts of utility.
However, until recently, nanotechnology developed for medical purposes has largely been
one-dimensional. Development and production of nanomaterials were done for the utilization of a
single function; to diagnose and/or provide information on a disease state, or to provide therapy for
the treatment of a disease state [186]. These nanoscale diagnostic agents and nanomedicines have
proven to be independently useful, with particular success being found in sequential utilization of
their single functions. To first make a diagnosis and acquire details on the progression of a disease,
and then to administer specific, personalized treatments to abrogate and possibly eliminate said
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disease based on previously acquired diagnostic information, has proven useful in patient
management. But these independent functions, diagnosis and therapy, have required independent
nanomaterials. Such a two-part strategy has proven ineffectual for disease states with diverse
presentations within the clinic and complicated underlying pathology. Furthermore, the most
significant diseases impacting humanity today have complex disease progressions.
The term “theranostics” was coined from the concept of combining both therapeutic and
diagnostic nanomaterials into a single platform [187]. Such combination would allow both
nanomaterials to be delivered together, allowing for concurrent treatment and monitoring of a
disease state. Theranostics is a cornerstone strategy for personalized medicines, allowing for
identification of subgroups of patients with specific clinical profiles that are most likely to respond
to specific therapies, while also identifying within those same subgroups patients that would have
adverse reactions to these same therapies [186].
We developed theranostic nanoparticles for real-time tracking of therapy biodistribution in
the treatment of HIV-1. Termed “multi-modal imaging theranostic nanoprobes”, such
nanotechnology allowed combined bioimaging, drug pharmacokinetics, and tissue biodistribution
tests in animal models [188]. Individual components include a diagnostic paramagnetic contrast
agent in cobalt ferrite, a diagnostic fluorescent component in incorporated Europium (Eu 3+), and
HIV-1 therapy in nanoformulated dolutegravir (DTG). Brief descriptions of each of these
components are described below.
1.9.1 Paramagnetic and superparamagnetic contrast agents
Magnetic resonance imaging (MRI) has proven to be a powerful and non-invasive
diagnostic modality since it’s development in the 1970’s [189]. MRI utilizes strong magnetic fields,
magnetic field gradients, and radio waves for interaction with the protons within a living organism,
allowing for generation of internal images. Specifically, MRI generates contrast based on intrinsic
differences between different tissue regions such as T1 (spin-lattice) and T2 (spin-spin) relaxation
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times, and proton density. In some disease states, it is possible to differentiate diseased tissue from
healthy tissue based on disease’s effect on these intrinsic differences. However, often times the
effect of disease pathology on these factors is too limited for any meaningful diagnostic information
to be discerned from the resulting images. Because of this, multiple “contrast agents” have been
developed that can drastically change the intrinsic relaxation times of specific tissues.
“Paramagnetic” materials can be defined as those that are weakly attracted by an external
magnetic field and form internal, induced magnetic fields in the direction of a specific applied
magnetic field [190, 191]. Paramagnetic contrast agents include manganese (Mn2+) and gadolinium
(Gd) that substantially shorten T1 relaxation of water protons, creating a brightened contrast in T 1
weighted MR images. Superparamagnetic contrast agents such iron oxide particles or cobalt ferrite
nanoparticles shorten T2 relaxation times of water protons, creating a “darkening” effect on T 2
weighted MR images [192]. Additionally, superparamagnetic contrast agents show much more
magnetic susceptibility compared that paramagnetic contrast agents, leading to an increase in
magnetic sensitivity.
1.9.2 Fluorescence
Fluorescence can be defined as a substance emitting light of a specific wavelength after
said substance has absorbed light or other electromagnetic radiation. Utilization of such a property
has proven useful in biological sciences, as application of fluorescent materials to a vehicle allows
for non-destructive tracking or analysis through different biological pathways. This can be
performed at specific emission frequencies in which there is no background from excitation light,
as very few biological components are naturally fluorescent. Such “fluorescent labeling” can be
done via a very large variety of different fluorophores such as dyes and fluorescent proteins, each
with a unique excitation and emission wavelength, molecular weight, and quantum yield [193].
Additionally, specific elements exhibit intrinsic fluorescence. Rare-earth doped phosphors such as
Terbium, Cerium, Lanthanum, and Europium form the basis for fluorescent lighting [194].
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Incorporation of rare earth element Eu3+ into our nanoparticle vehicle proved particularly useful,
exhibiting fluorescence and emission wavelengths at 410 nm and 660 nm, respectively. Europium
doping within the spinel ferrite structure of our theranostic nanoparticles allowed for subcellular
tracking using both in vitro and ex vivo confocal microscopy, as described in both chapter 2 and
chapter 3
1.9.3 Nanoformulated ARVs
The final component of our theranostic nanoparticles was that of nanoformulated ARV
drug, specifically the integrase inhibitor dolutegravir. Considerable innovation has occurred in the
production of long-acting ART regimens in efforts to reduce secondary toxicities, improved drug
adherence, and prevent new infections [195]. Ultimately, such goals center on drastically increasing
the half-life of ARV drugs by improving upon their hydrophobicity. Formation of cell and tissue
penetrate nanocrystals that are protected by biodegradable polymers allow the establishment of
drug depots within monocyte-macrophages, prolonging drug half-life. [195, 196] However, a major
drawback of developing long-acting ARV formulations is that biodistribution and pharmacokinetic
studies, often taking weeks to months, are tedious and burdensome. Incorporation of long acting
ARV drug into theranostic nanoparticles, in conjunction with other components, allows a much
more rapid screening of tissue biodistribution and pharmacokinetics, subsequently resulting in
much more timely pharmacodynamic improvements.
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CHAPTER 2
Synthesis, characterization, and in vitro testing of
multi-modal theranostic nanoformulations

48

2.1 Introduction
A major unmet need in the treatment of HIV-1 infection rests in long-term adherence to
antiretroviral therapy (ART). If brought into clinical practice, long-acting ART regimens would
substantively improve drug adherence, reduce secondary toxicities and prevent new infections.
These could ultimately facilitate the realization of an AIDS-free world [195, 197-201]. In efforts
to complete this task, we improved the hydrophobicity of existing antiretroviral drugs (ARVs),
leading to the formation of cell- and tissue-penetrant nanocrystals protected inside biodegradable
polymers. These were made to establish drug depots within monocyte-macrophages [202-207]. A
critical component for formulation development rests, in measure, on nanoparticle decoration with
macrophage-targeting moieties in order to best facilitate drug reservoir targeting. Such advances,
if realized, will speed the development of eradication measures or, at the least, make therapeutics
more accessible to larger patient populations. However, a significant obstacle remains in the ability
to rapidly screen drug formulation tissue biodistribution and pharmacokinetics (PKs) in order to
realize substantive pharmacodynamic (PD) improvements. This is of particular importance as,
while the half-lives of each of the few existing long-acting drugs measure in weeks or even months,
drug tissue distribution is limited [200, 208-212]. To overcome these technical and biologic
challenges, multimodal decorated nanoparticles were produced where hydrophobic ARVs and
bioimaging agents were encased in a single nanoformulation. All were placed into one “multimodal
imaging theranostic nanoparticle” using core-shell construction methods [213]. The surface of the
particle was coated with lipids decorated with targeting moieties, while the drug and image contrast
agents were incorporated into a polymeric core. The formed particles were rapidly taken up by
macrophages. Specifically, europium (Eu3+) doped cobalt ferrite (CF, EuCF) crystals and
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hydrophobic drug dolutegravir (DTG) were packaged in a polycaprolactone (PCL) core. A lipid
layer

coated

the

particle’s

“shell”.

L-α-phosphatidylcholine

(PC),

1,2-distearoyl-

phosphatidylethanolamine-methyl-polyethyleneglycol conjugate-2000 (DSPE-PEG2000) and 1,2dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) lipids enhanced particle biocompatibility and
lipophilicity, facilitating macrophage targeting [214]. Macrophage receptors sped entry of the
ligand-coated drug particles. The folic acid (FA) receptor on macrophages enhanced particle cell
entry [215-220]. Nanoparticles were produced with consistent size and stability, reflected in longacting slow effective drug release (LASER) ART profiles [202, 206]. This enabled depot formation
for viral reservoir targeting [206]. Overall, the newly generated theranostic nanoparticles provided
a platform for effective nanoformulated ARV development.

2.2 Materials and methods
2.2.1 Reagents
Iron(III) acetylacetonate (Fe(acac)3), cobalt(II) acetylacetonate (Co(acac)2), europium(III)
nitrate hydrate (Eu(NO3)3·5H2O), folic acid (FA), oleic acid, oleylamine, lipopolysaccharide
(LPS), poly(vinyl alcohol) (MW 30,000-70,000, 87-90% hydrolyzed), L-α-phosphatidylcholine
(PC) (from egg yolk), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT),
dicyclohexyl-carbodiimide, N-hydroxysuccinimide, low gelling temperature agarose, coumarin-6,
iron and cobalt standards for ICP-MS (TraceCERT®) and nitric acid (TraceSELECT®) were
obtained from Sigma-Aldrich, St. Louis, MO, USA. Polycaprolactone (PCL) (MW 43,000-50,000)
was

obtained

from

Polysciences,

Inc.

Warrington,

PA,

USA.

1,2-Distearoyl-

phosphatidylethanolaminemethyl-polyethyleneglycol conjugate-2000 (DSPEPEG2000) and 1,2dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) were obtained from Corden Pharma
International, Plankstadt, Germany. DTG was obtained from BOC Sciences, Shirley, NY, USA.
1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N- [amino(polyethyleneglycol)-2000] (DSPEPEG2000- NH2) was obtained from Laysan Bio Inc. Arab, AL, USA.
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2.2.2 Synthesis of DSPE-PEG2000-FA Conjugates
FA-modified DSPE-PEG2000 was synthesized by a multi-step process. FA was activated
by conversion to a N-hydroxysuccinimide ester (NHS-FA) [221]. FA (237 mg; 0.536 mmol, 1
equiv.) was dissolved in 10 mL of anhydrous dimethyl sulfoxide (DMSO, 10 mL) and triethylamine
(80 µL, 0.569 mmol, 1.1 equiv.) and allowed to stir at room temperature for 18 h under argon and
protection from light [222]. Dicyclohexylcarbodiimide (111 mg; 0.533 mmol, 1 equiv.) and Nhydroxysuccinimide (123 mg; 1.0 mmol, 2 equiv.) were added to the FA solution then stirred for
an additional 16 h. The resulting NHS-FA solution was separated from insoluble dicylohexylurea
by filtration then reacted with DSPE-PEG2000-NH2 (500 mg; 0.179 mmol, 0.3 equiv.). The
mixture was stirred for 3 days at room temperature under argon and light protection. The DSPEPEG2000-FA conjugate was precipitated from ether (~150 mL) and collected by centrifugation at
215 × g for 15 min. The pellet was dried under vacuum, dissolved in methanol (~25 mL) and
purified on a sephadex LH-20 column using a coumarin-6 dye as an indicator. The purified product
(~200 mL volume) was precipitated from ether and collected by centrifugation at 1950 × g for 10
min. The resulting pellet was lyophilized (Labconco Freezone 2.5, Kansas City, MO, USA) for two
days and yielded a light yellow powder. Covalent linkage of FA to DSPE-PEG2000-NH2 was
confirmed by 1H-NMR (Bruker Avance III HD, 500 MHz in deuterated DMSO). The final DSPEPEG2000-FA conjugate was stored at 4 °C
2.2.3 Production of EuCF-DTG “core-shell” nanoparticles
EuCF nanoparticles of 7.2 nm size were fabricated using solvothermal techniques [223]
and characterized for hydrodynamic size, size distribution, shape, structural configurations,
morphology, chemical composition and superparamagnetic properties. EuCF-DTG “core-shell”
nanoparticles were synthesized using a modified solvent evaporation process [213, 224].
Specifically, PCL (400 mg), DTG (30 mg) and EuCF (20 mg) were dissolved in DCM, methanol
and chloroform (oil phase), respectively. Fresh lipid mixtures were prepared by dissolution of PC
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(50 mg), mPEG2000-DSPE (25 mg) and DOPE (25 mg) in 5 mL of chloroform by bath sonication.
A EuCF-DTG primary emulsion was prepared by mixing EuCF, PCL and DTG solutions with
stirring for 6-8 h at 140 × g at room temperature. The secondary emulsion and shell layers for core
nanoparticles were prepared by making a thin film of lipids (PC, PEG2000-DSPE and DOPE) in a
round bottom flask through rotary evaporation (Büchi Rotavapor R-II, New Castle, DE, USA) of
chloroform followed by overnight vacuum-drying. The primary emulsion of EuCF-DTG was then
transferred into 30 mL of freshly prepared 1% (w/v) PVA and mixed by probe sonication (ColeParmer, Vernon Hills, IL, USA) at 20% amplitude for 10 min in an ice bath. The PVA served as a
surfactant in this emulsification step. The core nanoparticles were then transferred into the flask
containing the lipid film. The flask was steadily rotated with the core nanoparticles in a bath
sonicator followed by probe sonication at 20% amplitude for 10 min in an ice bath. Evaporation of
DCM was carried out under pressure at 35°C followed by overnight stirring. The nanoparticles
were purified by centrifugation of the suspension at 55 × g for 10 min, followed by centrifugation
of the supernatant at 35,1315 × g for 30 min at 10°C (Sorvall, Lynx-4000 super speed centrifuge,
Thermo Fisher Scientific, Waltham, MA, USA). The pellet was washed twice with PBS,
resuspended in PBS and stored at 4°C. For preparation of FA-EuCF-DTG nanoparticles, 25 mg of
DSPE-PEG2000-FA was used and the remainder of the synthesis followed the preparation of the
EuCF-DTG nanoparticles. For drug quantification from nanoparticles, ~30 mg of lyophilized
nanoparticles was dissolved in 10 mL of DCM: methanol (1:1 v/v) mixture. The mixture was then
bath sonicated for 30 min followed by centrifugation at 35,1315× g for 30 min. The supernatant
was collected and DCM was evaporated at room temperature. The drug in methanol was quantified
by HPLC.
2.2.4 Nanoparticle characterization
Powder X-ray diffraction (XRD) analysis was carried out in the 2θ range of 2–70° using a
PANalytical Empyrean diffractometer (PANalytical, Inc., Westborough, MA, USA) with Cu-Kα
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radiation (1.5418 Å) at 40 kV and 45 mA. A mask of 20 mm and divergence slit of 1/32° were used
on the incident beam path. A thin layer of the powdered nanoparticle was placed on a zerobackground silicon plate and continuously spun at a rate of 22.5°/s. The solid state PIXcel3D
detector (PANalytical, Inc.) was scanned at a rate of 0.053°/s. The PIXcel3D was equipped with a
beam monochromator to improve the signal-to-noise ratio. Magnetic characterization was
performed using a superconducting quantum interference device (SQUID) magnetometer
(Quantum Design, MPMS-XL, Quantum Design International (QDI), San Diego, CA, USA) at 300
K. Stability of the EuCF-DTG nanoparticle suspension was assessed over three weeks by
measuring hydrodynamic diameter and nanoparticle size distribution in saline on a Malvern
Zetasizer Nano-Series instrument (Malvern Instruments Ltd., Malvern, UK) at 4 °C. FTIR were
recorded on a Perkin-Elmer-spectrum attenuated total reflectance (ATR)-FTIR equipped with a
UATR-accessary (Perkin-Elmer, Inc., Waltham, MA, USA). Atomic-force microscopy (AFM) was
conducted using a Bruker Dimension Icon® Atomic Force Microscope (Bruker, Billerica, MA,
USA) equipped with peak-force tapping and scan-assist with Al reflection coating (spring constant
is 0.4 N/m and tip radius is ~2 nm, width 25 μm, thickness 0.65 μm, and length 115 μm). Multilayers
of nanoparticles were prepared by drop-casting diluted aliquots of aqueous nanosuspensions on
clean glass slides followed by slow evaporation of the solvent at room temperature. The images
were flattened using Nano-Scope Analysis software (Bruker, Billerica, MA, USA). Nanoparticle
morphology and structure were analyzed by transmission electron microscopy (TEM).
Nanoparticle suspensions were dried on a copper grid at room temperature and bright field images
were taken with exposure times of 2 s using the Tecnai G2 Spirit TWIN electron microscope (FEI,
Houston, TX, USA) operating at 80 kV. Images were acquired with an AMT digital imaging
system. Fluorescence spectroscopy was performed by SpectraMax® M3 Multi-Mode Microplate
Reader (Molecular Devices, LLC, Sunnyvale, CA, USA).
2.2.5 In vitro drug release study
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In vitro release study of DTG was performed using a USP dissolution testing system
(Sotax-AT7smart USP, SOTAX Corp. Westborough, MA, USA) with dialysis bag technique [225]
(Dialysis bag, MWCO 25 kD, Spectrum Laboratories, Inc., CA,USA). The DTG release
experiments were carried out in Dulbecco’s phosphate-buffered saline (DPBS; Thermo Fisher
Scientific, Waltham, MA, USA) with 2% (v/v) Tween-80. Five mg of DTG in EuCF nanoparticles
were placed in dialysis bags containing 3 mL of the release medium. The bags were placed in
stainless steel baskets and immersed in a container containing 1000 mL of release medium at a
temperature of 37±0.5 °C. One mL of each sample was withdrawn at regular time intervals and the
same volume was replaced with fresh release medium. Samples were further diluted and analyzed
for DTG content by HPLC. These studies were performed in triplicate for each sample, and the
average values were used in the data analyses. Furthermore, the release profiles of DTG from
nanoparticles were each fitted with Higuchi, Korsmeyer–Peppas, Elovich equation, parabolic
diffusion, Bhaskar-equation, and Modified-Freundlich mathematical models [226].
2.2.6 Isolation of culture of monocyte-derived macrophages (MDM)
Human peripheral blood monocytes were obtained by leukapheresis from hepatitis B and
HIV-1/2 seronegative donors, and purified by counter-current centrifugal elutriation [223]. Cells
were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen, Grand Island, NY,
USA) with 10% heat-inactivated pooled human serum (Innovative Biologics, Herndon, MA, USA),
1000 U/mL macrophage colony stimulating factor, 1% glutamine, 50 μg/mL gentamicin, and 10
μg/mL ciprofloxacin for 7 days to promote monocyte macrophage differentiation [227]. Cellular
uptake of the EuCF-DTG and FA-EuCF-DTG nanoparticles was determined in MDM cultured in
12-well plates at a density of 1.5 × 106 cells/well. Cells were treated with nanoparticles in medium
at a concentration of 5 μg iron/mL for 12 h. Nanoparticle uptake was assessed by measurement of
cell drug and iron concentrations without medium changes. Adherent MDM were scraped into PBS
at 2, 4, 8 and 12 h post treatment. Cells were pelleted by centrifugation at 1950 × g for 10 min at 4
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°C and briefly sonicated in 100 μL of a mixture of methanol:acetonitrile (1:1 v/v) then centrifuged
again at 10,844 × g for 10 min at 4 °C. Supernatant was used for DTG quantification by reversed
phase HPLC. Parallel sets of cells were collected into nitric acid (69%) for ICP-MS analysis of iron
and cobalt content.
2.2.7 Immunocytochemistry and transmission electron microscopy (TEM)
Macrophage nanoparticle uptake and subcellular distribution were studied by confocal
microscopy and TEM [207, 223, 228]. To determine subcellular localization of EuCF-DTG
nanoparticles, MDM were treated with nanoparticles at a concentration of 5 μg iron/mL for 8 h.
For immunofluorescence staining, cells were washed three times with 1 mL of PBS (10 min each
step) and fixed with ice cold 4% paraformaldehyde (PFA) at room temperature for 30 min. The
cells were then washed with PBS (1 mL, 3X) for 10 min at each step and treated with a
permeabilizing reagent (0.5% v/v Triton-X-100) for 15 min at room temperature. Cells were again
washed with PBS (1 mL, 3X) for 10 min at each step. Cells were treated with a blocking solution
(5% w/v BSA in PBS and 0.1% v/v Triton-X-100) for 1 h at room temperature and quenched with
50 mM NH4Cl for 15 min. The cells were washed once with 0.1% Triton-X-100 in PBS and
incubated with primary antibody (Rab7 (SC-10767) for late endosomes, Rab11 (SC-6565) and
Rab14 (SC-98610; Santa Cruz Biotechnology, Dallas, TX, USA) for recycling endosomes and
LAMP-1 (NB120-19294; Novus Biologicals, Littleton, CO, USA) for lysosomes) diluted in
blocking solution (5% BSA and 0.1% Triton-X in PBS; antibody: blocking solution 1:25) overnight
with shaking at 4 °C. Cells were then incubated with secondary antibody (AlexaFluor-594;
Thermo-Fischer Scientific, Waltham, MA, USA) and diluted in blocking solution (1:50) for 2 h at
room temperature. Slides were covered with ProLong Gold AntiFade reagent with DAPI (4′,6diamidino-2- phenylindole; Thermo-Fischer Scientific, Waltham, MA, USA) and imaged using a
63X oil objective on an LSM 710 confocal microscope (Carl Zeiss Microimaging, Inc., Dublin,
CA, USA). Zeiss LSM 710 Image browser AIM software version 4.2 was used to determine the
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number of pixels and the mean intensity of each channel. For TEM analysis, MDM (1.5 × 106
cells/mL) were incubated in 12-well plates for 8 h with nanoparticles (5 μg/mL of iron
concentration). After treatment, cells were centrifuged at 1950 × g for 10 min at 4 °C. Cell pellets
were suspended in a solution of 2% glutaraldehyde and 2% PFA in 0.1 M Sorenson’s phosphate
buffer (pH 6.2) for a minimum of 24 h at 4 °C. The cell fixation and block preparation methods are
available in the Supplementary Material. MDM internal morphology was analyzed by cutting thin
sections of control and nanoparticle-loaded MDM using a Leica UC6 ultramicrotome (Leica
Microsystems, Inc., Buffalo Grove, IL, USA) then placed on 200 mesh copper grids. MDM and
nanoparticle samples were examined using the Tecnai G2 Spirit TWIN electron microscope (FEI,
Houston, TX, USA) operating at 80 kV. Images were acquired with an AMT digital imaging
system.
2.2.8 Antiretroviral activity
Antiretroviral efficacies of the EuCF-DTG and FA-EuCF-DTG nanoparticles in HIV-1 infected MDM were evaluated as described [196, 229]. In brief, MDM were treated with 6.25 µM,
12.5 µM, or 25 µM (DTG content) of native DTG, EuCF-DTG or FA-EuCF-DTG nanoparticles
for 8 h. Cells were then cultured in fresh medium without nanoparticles. At days 1 and 5 posttreatment, MDM were then treated with HIV-1ADA for 16 h at a multiplicity of infection (MOI) of
0.1 infectious virions per cell. Cells were maintained for 10 days post infection with a full media
exchange occurring 2 days prior to analysis. The culture supernatants were assessed for progeny
virion formation by measuring reverse transcriptase (RT) activity [230]. At this time, cells were
washed with PBS and fixed in 4% PFA for 15 min. Fixed cells were blocked using 10% BSA
containing 1% Triton-X 100

2.3 Results
2.3.1 Structural and physicochemical nanomaterial characterization
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Theranostic multimodal EuCF-DTG lipid-PCL “core shell” nanoparticles were synthesized
to have fluorescence, exhibit paramagnetism for MR imaging, and to package ARV therapy as
lipid-PCL “core-shell” nano-constructs have previously been shown to be effective vehicles.
Characterization of FA-decorated EuCF-DTG nanoparticles is outlined in Figure 2.1A
Composition of the cores of the nanoparticles was PCL:DTG:EuCF (1:0.075:0.05 w/w/w)
surrounded by a lipid shell of PC:DSPE-PEG:DOPE (1:0.5:0.5 w/w/w). For FA-EuCF-DTG
nanoparticles, a lipid ratio of PC:DSPE-PEG2000-FA:DOPE (1:0.5:0.5 w/w/w) was used.
Synthesized theranostic nanoparticles exhibited fluorescence and emission wavelengths at 410 nm
and 660 nm, respectively. Transmission electron microscopy (TEM) determined the internal
morphology of the nanoparticles, with TEM images in Figure 2.1B showing nanoparticles
possessing a spherical shape with a core structure composed of the PCL surrounded by multiple
lipid surface layers. TEM images of nanoparticles without EuCF are shown in Figure 2.1B (i-ii).
Complete embedding of the EuCF within the PCL core matrix is illustrated in Figure 2.1B (iii-iv).
Characterization of the surface topography of nanoparticle was performed using atomic force
microscopy (AFM) and suggested the lipid layers covered the spherical nanoparticles with smooth
and uniform surfaces, as shown in Figure 2.1C. X-ray diffraction (XRD) patterns of EuCF and
EuCF-DTG are shown in Figure 2.1D. Comparison of diffractograms of EuCF-DTG with that of
native EuCF confirmed polycrystalline nature of the theranostic nanoparticles. Furthermore, XRD
diffractogram patterns of the EuCF-DTG nanoparticles displayed peaks corresponding to organic
and inorganic EuCF phases, showing incorporation of all necessary components into a finalized
nanoparticle. Diffraction peaks exhibiting a decrement in EuCF intensity do so because of the
masking effect of both PCL and lipids [231]. Broader diffraction peaks present in the EuCF-DTG
XRD were attributed to the to the presence of nanosized EuCF crystals [231]. EuCF-PCL
nanoparticles showed a saturation magnetization value of 7.5 emu/g and a sigmoid curve via
superconducting quantum interference device (SQUID) analysis shown in Figure 2.1E,
demonstrating that the nanoparticles were superparamagnetic at 300 K [223]. Dynamic light
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scattering (DLS) was utilized to determine the hydrodynamic size of monodispersed nanoparticles,
as shown in Figure 2.1F. Average nanoparticle size was 253 nm in diameter with a polydispersity
index (PDI) of 0.14 and ~6.2% w/w DTG drug loading. Drug release from theranostic EuCF-DTG
nanoparticles was found to cumulative with ~30% of drug released within 5 days and 36% by day
10 as shown in figure 2.1G. Additionally, it was found that when the cumulative percentages of
DTG release from experimental formulations was plotted vs time that ~40% of DTG was released
in 12 days from EuCF-DTG. Several kinetic models were used to better understand mechanism of
DTG release from the EuCF-DTG nanoparticles: experimental in vitro release data set was fitted
by the Higuchi, Korsmeyer-Peppas, parabolic diffusion, Elovich equation, Bhaskar equation, and
a Modified-Freundlich kinetic model [225, 226]. Of the kinetic models tested, the parabolic
diffusion and Bhaskar equations showed a theoretical DTG release pattern that was close to the
experimental profile. Therefore, the kinetics of DTG release are governed by diffusion-controlled
release phenomena.
Theranostic nanoparticles with a folic acid (FA) receptor targeting ligand were prepared
by incorporating FA-PEG-DSPE onto the surface of EuCF-DTG nanoparticles. Specifically,
chemical shifts at 3.3-3.6 ppm in the 1H-NMR spectrum correspond to repeating ethylene oxide
(CH2CH2O) hydrogens of the PEG component of the lipid, while the aromatic protons from FA
are at 7.7 and 8.3 ppm. Chemical shifts corresponding to DSPE are seen at 0.9 ppm (-CH3), 1.1
ppm (-CH2) and 2.1 ppm (-CH2CO) [40]. The EuCF nanoparticles contain characteristic
absorption bands of octahedral metal-oxygen (M–O) bonds of the ferrite lattice [21]. DTG showed
characteristic absorption bands at 1272 (-C-N), 1588 and 1650 (-C=O), 2983 (-C-H) and 3082 cm1 (-C-H aromatic rings). The IR spectrum of PC demonstrates a characteristic C=O stretching band
at 1740 cm−1 and PO−2 asymmetric double bond stretching bands at 1250 cm−1. The spectra of
both PEG–DSPE and PC demonstrate a carbonyl ketone band at 1740 cm−1 and a CH alkylstretching band at 2891 cm−1. EuCF-DTG nanoparticles showed characteristic absorption bands
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belonging to EuCF, DTG, PCL and lipids, along with bands at 2951 cm−1 (asymmetric), 2873 cm1

(symmetric) due to (−CH2), and 1725 cm-1 for the carbonyl (−C=O) stretching of PCL [213]. The

FTIR results indicate that DTG and EuCF interact strongly with PCL and lipids.
2.3.2 Macrophage uptake and subcellular distribution
Cellular uptake of theranostic nanoparticles was determined in MDMs. Cells were treated
with FA-EuCF-DTG or EuCF-DTG nanoparticles (based on 5 µg/ mL iron) for up to12 hours, with
cells washed in phosphate-buffered saline (PBS) and collected into nitric acid (69.0%) at either 2,4,
8, or 12 hours post-treatment. Cobalt and DTG concentrations were determined by ICP-MS and
UPLC-MS/MS, respectively. As shown in Figure 2.2A, the uptake of FA-EuCF-DTG nanoparticles
was significantly greater than that of EuCF-DTG nanoparticles at both 8 hours and 12 hours, as
determined by iron content analysis. Cell iron concentrations exhibited a 4.5-fold greater amount
of iron in cells treated with FA-EuCF-DTG nanoparticles are compared to EuCF-DTG
nanoparticles at 12 hours post treatment. Cellular DTG levels show results corresponding to iron
levels, with Figure 2.2B exhibiting FA-EuCF-DTG nanoparticles providing higher amounts of drug
compared to EuCF-DTG nanoparticles. Visualization of cellular uptakes of nanoparticles and their
subsequent subcellular distribution was performed using confocal microscopy and the inherent
fluroscent properties of Eu3+ within nanoparticles (Figure 2.2C). Specifically, subcellular
distribution of EuCF-DTG nanoparticles was determined by immunostaining with various different
endosomal protein antibodies: Rab7 representing late endosomal sorting, Rab11 and Rab14
representing recycling endosomal compartments, and LAMP-1 representing the lysosomalassociated membrane protein-1. Primary antibodies were detected using a red Alex Fluor 594
secondary antibody. Figure 2.2D shows the yellow color associated with the colocalization of
EuCF-DTG nanoparticles (green) and endosomal proteins (red) [196]. These resulting images
suggest that EuCF-DTG nanoparticles were distributed mainly in recycling endosomal
compartments throughout the cytoplasm (Rab11) and in the perinuclear region (Rab14).
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Distribution within lysosomal regions (LAMP-1) and early endosomal compartments (Rab7) was
less than that seen in recycling endosomes. Additionally, TEM was used to investigate the
subcellular distribution of nanoparticles (Figure 2.2F-H) Typical macrophage morphology is
illustrated by TEM of a control cell in Figure 2.2E, and visually there appears to be a greater amount
of FA-EuCF-DTG nanoparticles that were internalized as compared to EuCF-DTG. Macrophage
morphology was not altered by the presence of theranostic nanoparticles.
2.3.4 Antiretroviral activities of EuCF-DTG and FA-EuCF-DTG nanoparticles.
MDM infected with HIV-1ADA, a prototype macrophage-tropic strain, were used to assess
the antiretroviral activities of EuCF-DTG and FA-EuCF-DTG nanoparticles [196]. MDM were
treated with nanoparticles are various DTG concentration while native drug served as a control.
MDM were infected at a multiplicity of infection (MOI) of 0.1 infectious viral particles per cell
after 1 day post-treatment. Progeny HIV-1 virion production was determined by reverse
transcriptase (RT) activity in cell culture fluids 10 days after infection, with intracellular p24
antigen expression also being measured within cells. Figure 2.3A Illustrates that RT activity was
suppressed by 6.25, 12.5, and 25 µM DTG (both native and nanoparticles), with parallel results
being displayed in HIV-1 p24 staining (Figure 2.3B). Fewer HIV-1 p24 positive cells were detected
with EuCF-DTG and FA-EuCF-DTG nanoparticles than in cell treated with native DTG at day 1
after treatment.

2.4 Discussion
The use of LASER ART as a viable alternative to conventional ARV therapy has been
realized in our laboratories previous publications [195, 199, 202, 232, 233]. LASER ART can affect
regimen changes, improve patient ARV adherence, reduce systemic toxicities, ease pill burdens
and limit new viral infections [201, 233-235]. Nonetheless, hurdles remain in the conversion from
commonly used pills into long-acting drug formulations. Our laboratories have taken a singular
approach in converting hydrophilic or partially hydrophobic drugs into lipophilic prodrugs and in
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using decorated polymers to target reservoirs of viral infection. This strategy seeks to optimize drug
delivery, biodistribution and PK profiling [195-197, 199, 229]. However, the best strategy to screen
newly synthesized and decorated nanoparticles remains unrealized. As therapeutic success of
formulations is linked to nanoparticle size, shape, decoration, encapsulation and drug half-life,
screening is cumbersome. Moreover, how best to assess drug penetrance into “putative” viral
reservoirs remains a major obstacle in translational research efforts. We now posit that one means
to assess the therapeutic potential of LASER ART is through theranostic probes [223]. Thus, stable
ultra-sensitive EuCF nanoparticles encapsulating ARV and surrounded by lipids [213] were made.
Such theranostic screens used to assess cell-based drug delivery holds potential for approaches to
develop eradication strategies to cure HIV-1/AIDS.
EuCF-DTG nanoparticles were prepared via an emulsification solvent evaporation method
using dichloromethane (DCM) as the organic phase. The mechanism of formation of
multicomponent nanosystems is described as a combination of inorganic nanoparticles (EuCF) and
organic, hydrophobic, biodegradable PCL forming the core of the particles with amphipathic lipids
(DOPE, mPEG2000-DSPE and PC) constituting the shell of the multicomponent nanosystems.
Importantly, PCL has a good solubility in DCM, which by diffusing towards the oil phases
enhances the hydrophobic drug (DTG) retention in the core of EuCF-PCL, significantly improving
encapsulation efficiency. Additionally, when the EuCF-PCL and drug solution (in DCM) is
dispersed into the aqueous polyvinyl alcohol (PVA) surfactant, the agitation of the interface
spontaneously produces a bigger interfacial area, which leads to nano-sized quasi-emulsion
droplets of EuCF and DTG encapsulated in PCL. Simultaneously, combinations of amphipathic
lipids serve as secondary surfactants on the surface of nanoparticles. Meanwhile, methanol
specially diffuses from droplets due to its lower affinity for EuCF, DTG and PCL, and higher
affinity for PVA. Continuous diffusion of methanol out of the droplets and the coacervation of PVA
led to formation of nanoparticles with the lipids mixture acting as secondary surfactants.
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Conclusively, the evaporation of residual solvent and subsequent solidification of EuCF-DTG coreshell nanoparticles, together with stirring in PVA solution, caused greater reduction in surface
tension, leading to formation of the resultant particles in the nanometer range and with spherical
morphologies.
DTG was released slowly over a time period of 12 days. The prolonged release profile
could be attributed to physicochemical properties of the EuCF-DTG core-shell. Drug release
occurred by diffusion through the lipid barriers followed by erosion of the core polymer by
hydrolytic degradation. These hypotheses were cross validated by kinetic parabolic diffusion and
Bhaskara equation models indicative of the low permeability of water in the particle’s interior PCL
core-shell. Due to the hydrophobic nature of DTG, it is probable that the drug was incorporated at
the core of the particles during the solvent evaporation process. It is expected that nanoparticles
prepared by solvent evaporation slowly release the drug due to the hydrophobic nature of the core
materials.
Macrophage uptake and subcellular nanoparticle distribution enables drug delivery to HIV1 infection sites [13, 236, 237]. Uptake of the lipid nanoparticles is greater than that of silica
platforms [223]. The fluorescence modality of the EuCF-DTG and FA-EuCF-DTG nanoparticles
proved useful in identifying nanoparticle subcellular distribution. We assayed macrophage
nanoparticle uptake by measurements of both iron and DTG. We then examined nanoparticle
subcellular localization using antibodies specific to subcellular compartment proteins and showed
that the nanoparticles were distributed preferentially within recycling endosomes. Previously, we
and others have demonstrated preferential localization of nanoformulated rod-shaped nanoparticles
containing ARV drugs in similar compartments [196, 229]. HIV-1 persists in recycling endosomes
[196, 202, 229] supporting the importance of subcellular ART depots.
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Overall, EuCF-DTG “multimodal imaging theranostic nanoprobes” were made to facilitate
the development of targeted LASER ART. The lipid-encapsulated EuCF nanoparticles can fulfill
this role by providing a flexible platform for the design of diagnostic and therapeutic applications.
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2.5 Figures
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Figure 2.1 Synthesis and characterization of lipid-coated core-shell nanoparticles. (A) A
schematic illustration of the design of multimodal FA-EuCF-DTG core-shell nanoparticles is
presented. (B) TEM images of nanoparticles, (Bi) PCL-DTG (without EuCF) nanoparticles, (Bii)
FA-functionalized PCL-DTG (without EuCF) nanoparticles, (Biii) EuCF-DTG nanoparticles, and
(Biv) FA-EuCF-DTG nanoparticles. The lipid layers (average thickness of ~15 nm) appeared as a
solid corona around the “hard” PCL matrix. EuCF nanocrystals (red arrows) appear as crystalline
hexagonal-shaped monodispersed structures in the PCL matrix. (C) Characterization of the size
distribution of EuCF-DTG nanoparticles by AFM. (Ci) AFM topographic distribution of EuCFDTG nanoparticles and, (Cii) a corresponding 3D view. (D) X-ray powder diffraction (XRD)
patterns of EuCF and EuCF-DTG nanoparticles. (E) Evaluation of the magnetic properties of the
nanoparticles by magnetic-hysteresis (M-H) curves measurements using SQUID. Data are recorded
at 300 K. (F) Hydrodynamic size distribution of nanoparticles determined by dynamic light
scattering (average nanoparticle size of ~253 nm) and (G) in vitro release profiles of DTG in PBS
(pH 7.3) at 37±0.5 °C
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Figure 2.2 Macrophage nanoparticle uptake and subcellular distribution. Uptake and
subcellular distribution of nanoparticles was determined in human MDM (monocyte-derived
macrophage). EuCF-DTG and FA-EuCF-DTG nanoparticles were detected in cells at 2 h. EuCFDTG and FA-EuCF-DTG nanoparticles were added to MDM culture at a concentration of 5 μg/mL
iron. (A) Iron concentrations in MDM following nanoparticle uptake over 12 h and (B)
corresponding DTG levels; data represent mean ± SEM (n = 3). Statistical differences were
determined using one-way ANOVA among groups followed by Student’s t-test for differences
between groups at each time-point, ****p < 0.0001. (C) Intracellular nanoparticles were detected
by confocal microscopy at an excitation wavelength of 488 nm and emission wavelength of
510/520 nm. (D) For subcellular distribution analysis, MDM were treated with EuCF-DTG
nanoparticles (5 μg/mL based on iron; green) for 8 h and then immunostained with Rab7, Rab11,
Rab14 and LAMP-1 antibodies and Alexa Fluor 594-labeled secondary antibody (red) to visualize
nanoparticle and organelle co-registration. The yellow (merged) shows overlap of nanoparticles
and Rab compartments. DAPI (blue) stain indicates cell nuclei. Images were captured with 63X
objective on a Zeiss LSM 710 confocal microscope. Scale bars = 20 μm. (E-H) TEM ultrastructural
evaluation of macrophage nanoparticle uptake and subcellular distribution. Nanoparticles were
added to MDM cultures for 8 h. Cells were fixed and processed for TEM. (E) Typical internal
morphology of control macrophages is shown. Detailed evaluation of membrane-bound
intracellular structures at areas of interest is presented in magnified panel ii and iii. (F–H)
Intracellular uptake of (F) PCL-DTG (without EuCF), (G) EuCF-DTG and (H) FA-EuCF-DTG
nanoparticles. Areas of interest bordered with dotted red lines are presented in corresponding highresolution images (ii–iii) and illustrate nanoparticles within membrane-bound intracellular
structures. All nanoparticle types were internalized and entrapped in endosomal vesicles in the
macrophages. Images of macrophages treated with FA-functionalized nanoparticles reveal a higher
number of nanoparticles internalized in vesicles compared to non-decorated particles. EuCF-DTG
and FA-EuCF-DTG nanoparticles are seen as black punctate structures encapsulated in white
polymeric nanoparticles within membrane-bound endosomes
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Figure 2.3 Antiretroviral activity measurements. Antiretroviral activity was determined in
MDM treated for 8 h with free DTG, EuCF-PCL, EuCF-DTG or FA-EuCF-DTG nanoparticles
(6.25, 12.5 and 25 μM DTG) and then infected with HIV-1ADA at a multiplicity of infection
(MOI) of 0.1 at day 1 after drug loading. At 10 days after infection, progeny HIV virion
production was determined by RT activity in the cell culture fluids. (A) HIV replication was
determined 10 days after infection by HIV RT activity of day 1. Statistical differences were
determined using one-way ANOVA among groups; we used Tukey’s test to correct for multiple
comparisons. *p < 0.05; **p < 0.01; ***p < 0.001. (B) HIV p24 staining (scale bar = 200 μm).
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CHAPTER 3
In vivo and ex vivo biodistribution studies of multimodal theranostic nanoformulations in rats and rhesus
macaques
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3.1 Introduction
To realize the potential of long acting viral reservoir penetrating drugs, pharmacokinetic
and pharmacodynamic profile assessment must be performed to minimize on and off-target effects.
Current PK and PD experimental assessments often take weeks to months to perform, and with
multiple innovative strategies coming to the forefront of development, such timeframes have
proved too tedious and time consuming. To overcome these technical and biologic challenges,
multimodal decorated nanoparticles were produced where hydrophobic ARVs and bioimaging
agents were encased in a single nanoformulation. All were placed into one “multimodal imaging
theranostic nanoparticle” using core-shell construction methods [213]. This allowed real-time
assessment of ARV biodistribution and activity [223]. Synthesized nanoparticles were deployed for
sensitive MRI tests. Such testing facilitated PK analyses and monitoring of drug-loaded
nanoparticle distribution into tissue reservoirs of viral infection. The core-shell structure was
engineered to carry ARVs that include DTG (EuCF-DTG), while demonstrating excellent
relaxivity profiles of r2 = 564 mM-1 s-1 and r2 = 546 mM-1 s-1 (targeted nanoparticles) in saline and
r2 = 876 mM-1 s-1 and r2 = 850 mM-1 s-1 (targeted nanoparticles) in cells. The Eu3+ component
enabled fluorescence imaging for histological validation of cell localizations of drug-loaded
nanoparticles [223]. DTG release from EuCF-DTG nanoparticles provided real-time validation of
drug biodistribution, as EuCF-DTG nanoparticles are rapidly endocytosed and retain potent
antiretroviral activity. Confocal microscopy with Eu3+ fluorescence showed nanoparticles in
cytoplasmic Rab compartments that affect vesicle trafficking and ARV depot formation [195, 202,
238, 239]. Following synthesis and particle characterization, bioimaging tests reflected drug
biodistribution after parenteral injection in rats and rhesus macaques. No secondary metabolic or
histopathological alterations were observed.

3.2 Materials and methods
3.2.1 MRI relaxometry measurements
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EuCF-DTG and FA-EuCF-DTG nanoparticle suspensions with an iron concentration
ranging from 0.2 to 2 μg/mL were prepared in DPBS. A 1.5% w/v agar gel was prepared by adding
150 mg of low melting agar in 10 mL of PBS at 70°C for 30 min. Phantom gels containing
nanoparticles were prepared by mixing 100 μL of a 1.5% (w/v) agar solution that was preheated to
60°C to prevent gelation with 100 μL of the nanoparticle suspension. Experiments were performed
in triplicate at each concentration. In order to make sure that no air bubbles were present, the
nanoparticle suspensions and agar gels were vortexed thoroughly while warm in 250 μL eppendorf
tubes and then rapidly cooled in an ice bath. MRI tests were performed using eppendorf tubes
containing the fixed nanoparticles in agar gels. MRI data were acquired on a 7T/16 cm Bruker
PharmaScan MRI system (Bruker; Ettlingen, Germany). T2-relaxtion maps were generated using
a CPMG (Carr Purcell Meiboom Gill sequence) phase-cycled multi-echo sequence. Single slice
(0.5 mm slice thickness) data were acquired with 3000 ms repetition time, 50 echoes (echo times
TEn = n x 10 ms; n = 1), 256 x 128 acquisition matrix, 50 x 50 mm field of view (FOV), 2 averages,
for a total scan time of 13 min. For T2 relaxation time measurements in MDM, as described in our
previous study [223], monocytes were seeded onto 100 mm culture plates at a concentration of 106
cells/mL and differentiated into macrophages in the presence of MCSF for seven days. Following
this, MDM were treated with nanoparticles (5 µg iron/mL) for 8 h and then the treatment medium
was removed and cells washed three times with DPBS. Cells were scraped into DPBS, collected
by centrifugation (1950 × g for 10 min at 4 °C) and suspended at various cell concentrations
containing 1.5% w/v agar in 250 μL eppendorf tubes. For T2 map measurements, CPMG phasecycled 3-dimensional multi-echo sequence data was acquired with 250 ms repetition time, 48
echoes (echo times TEn = n X 2.618; n = 1,…,48), 128 × 128 × 64 acquisition matrix, 70 × 64.76
× 42.38 mm FOV, one average, for a total scan time of 34 min.
3.2.2 EuCF-DTG and FA-EuCF-DTG nanoparticle biodistribution in rats
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In vivo biodistribution of nanoparticles was determined in male Sprague Dawley rats (160–
170 g) obtained from Charles River Laboratories (Wilmington, MA, USA). Animals were housed
in the University of Nebraska Medical Center (UNMC) laboratory animal facility according to
Association for Assessment and Accreditation of Laboratory Animal Care guidance. All protocols
related to animal experiments were approved by the UNMC Institutional Animal Care and Use
Committee, and met the requirements of the UNMC ethical guidelines set forth by the National
Institutes of Health. Rats were divided into multiple groups dependent on their route of injection
and planned sacrifice time point of 2, 5, or 10 days post-injection. 24 hours prior to nanoparticle
treatment, rats were given 5 mg/kg lipopolysaccharide (LPS) by intraperitoneal injection to engage
the innate immune system and affect macrophage activation in analogous manners as would be
seen following HIV-1 infection. Rats were MRI scanned prior to injection of the EuCF-DTG
nanoparticles (2 mg iron/kg iron content) and at 2, 5 and 10 days post-injection to determine
nanoparticle biodistribution and integrity. Assessment of the effects of FA targeting was performed
by administration of FA-EuCF-DTG nanoparticles in rats by either IM or IV injection. MRI
scanning was performed pre-injection and 5 days after injection for comparison tests of EuCF-DTG
administered animals. MRI was performed using the same 7T/16 cm Bruker PharmaScan that was
used for phantom data acquisition. Both T2 ∗-weighted high-resolution imaging and T2 mapping
were used to determine the biodistribution of EuCF-DTG nanoparticles. T2 ∗-weighted MRI was
performed using a 3D spoiled gradient recalled echo sequence with 10 ms repetition time, 2.7 ms
echo time, 15° pulse angle, 256 × 196 × 128 acquisition matrix, 75 × 57.5 × 37.5 mm FOV, six
averages, for a total scan time of 25 min. For T2 mapping, CPMG phase-cycled 3-dimensional
multi-echo sequence data were acquired with 24 echoes (echo times TEn = n × 2.718 ms; n = 1, 2,
…,24), 400 ms repetition time, 128 × 128 × 64 acquisition matrix, 70 × 64.76 × 42.38 mm FOV,
one average, for a total acquisition time of 34 min. T2 relaxation times were computed at each pixel
and generated maps using custom computer programs written in Interactive Data Language (IDL;
Exelis Visual Information Solutions; McLean, VA, USA). These maps were constructed at pre-
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injection and 24 h post-injection of nanoparticles using the even-echo images from the CPMG
phase cycled imaging data. Estimation of T2 relaxation times from even echoes only minimizes the
measurement errors due to the imperfection of high-power pulses [240]. The region of interest
(ROI) analysis was performed using Image-J software (http://imagej.nih.gov/lj). The
concentrations of nanoparticles were determined from the change in relaxivity rate (ΔR2 =
1/T2postinjection − 1/T2preinjection) and the nanoparticle relaxivity (r2) per mmol was
determined as the slope of iron concentration versus R2 measured ex vivo
3.2.3 Plasma and tissue drug, iron, and cobalt animal tissue quantifications
Drug concentrations in animal plasma and tissues were determined by UPLC-tandem mass
spectrometry (UPLC-MS/MS) using a Waters Acquity H-class UPLC- Xevo TQ-S micro system
(Waters Corp, Milford, MA, USA). For plasma drug quantitation, 25 μL of sample was added into
1 mL acetonitrile, followed by addition of 10 µL of internal standard (IS) solution to achieve a final
IS concentration of 50 ng/mL DTG-d3 (Clearsynth Canada Inc, Mississauga, ON, Canada) after
reconstitution. Samples were then vortexed and centrifuged at 17,000 g for 10 min at 4°C.
Supernatants were dried using a Thermo Scientific Savant Speed Vacuum (Waltham, MA) and
reconstituted in 100 µL 50% (v/v) acetonitrile in MS-grade water. Standard curves were prepared
in blank rat plasma in the range of 0.2–00 ng/mL. For tissue analyses, 100 mg of tissue was
homogenized in 4 volumes of 90% (v/v) acetonitrile in MS-grade water using a Qiagen Tissue
Lyzer II (Valencia, CA, USA). To 100 µL of tissue homogenate 80 µL of acetonitrile, 10 µL of
50% acetonitrile (v/v) was added in MS-grade water, and 10 µL IS. Standard curve samples were
prepared using equivalent tissue matrix dilutions, 80 µL of acetonitrile, 10 µL of 50% acetonitrile
(v/v) in MS-grade water spiked with standard drug concentrations, and 10 µL of IS.
Chromatographic separation of 10 µL of plasma or tissue samples was achieved with an Acquity
UPLC-BEH Shield RP18 column (1.7 µm, 2.1 mm x 100 mm) using a 10-min gradient of mobile
phase A (7.5 mM ammonium formate in Optima-grade water adjusted to pH 3 using formic acid)
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and mobile phase B (100% Optima-grade acetonitrile) at a flow rate of 0.25 mL/min. The initial
mobile phase composition of 40% B was held for the first 3 min, increased to 86% B over 0.5 min
further, held constant for 5 min, then reset to 40% B over 0.25 min and held constant for 1.25 min.
DTG was detected at a cone voltage of 10 volts and collision energy of 25 volts. Multiple reaction
monitoring (MRM) transitions used for DTG and DTG-d3 were 420.075 > 277.124 and 422.841 >
129.999 m/z, respectively. Spectra were analyzed and quantified by Mass Lynx software version
4.1. DTG quantitations were based upon drug peak area to internal standard peak area ratios. Iron
and cobalt levels were quantified by inductively coupled plasma mass spectrometry (ICP-MS) on
an Agilent Technologies ICP-MS 7500cs (Santa Clara, CA) and an ESI SC-4 high-throughput
autosampler (Elemental Scientific Inc., Omaha, NE) [241]
3.2.4 SIV-infected rhesus macaques
Three female rhesus monkeys were obtained from the Yerkes National Primate Research
Center. The monkeys were infected with SIVmav239 by an intravenous injection route 350 days
prior to drug administration. The monkeys had also been infected with Zika virus subcutaneously
175 days prior to this study. All animals had cleared Zika virus but were productively chronically
infected with SIV. EuCF-DTG nanoparticles were prepared under GLP conditions as above and
given to animals by intramuscular injection at a dose of 2 mg/kg based on iron on day 0. Animal
health was monitored daily and injection sites were examined closely under anesthesia on days 3
and 7; no reaction was noted. Blood was collected in K-EDTA tubes and plasma prepared on day
-5, day 0, day 3 and day 7; CSF was collected without additives in tubes on day 0 and day 7. On
day -2 pre- and day 5 post- EuCF-DTG nanoparticle administration, MRI was performed on the
three animals.
3.2.5 MRI tests for EuCF-DTG nanoparticle biodistribution in rhesus macaques
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Biodistribution of EuCF-DTG nanoparticles in rhesus macaques was determined using a
Philips Achieva (Briarcliff Manor, NY, USA) 3.0T MRI scanner. T2-weighted high-resolution
imaging and T2 mappings were obtained. High resolution T2-weighted images were acquired using
a turbo spin echo (TSE) sequence with 1428.6 ms repetition time, 90 ms echo time, 90° flip angle,
116 echo train length, 22 slices (3.5 mm slice thickness; 4.5 mm spacing between slices), 360 ×
360 acquisition matrix, 360 × 360 mm FOV, 6 averages, for a total scan time of 31.42 min. A multiecho TSE sequence was used for T2 relaxation time mapping. Images were acquired with 2000 ms
repetition time, 16 echoes (echo times TEn = n x 6 ms; n = 1, …,16), 288 x 288 acquisition matrix,
360 × 360 mm FOV. This sequence was repeated to cover multiple coronal slices (12 slices for preinjection and 16 slices for post-injection, 3.5 mm slice thickness, 4.5 mm spacing between slices).
T2 relaxation time maps were created using custom-developed computer programs using IDL
programming language. ROI analysis was performed using ImageJ software.
3.2.6 Tissue analyzes from treated rhesus macaques
After imaging on day 5, bone marrow and lymph node biopsies were performed on two of
the animals. The third animal was sacrificed on day 7, and fluids and tissues were collected for
study. At necropsy, splenomegaly and lymphadenopathy were present (consistent with chronic SIV
infection), and EuCF-DTG nanoparticles were present in the gall bladder, confirmed by ICP-MS
(cobalt = 0.476±0.037 μg/g). Complete blood counts and metabolic panels were performed by the
UNMC Department of Pathology and Microbiology / Nebraska Medicine Clinical Laboratory
Services. All animal experimentation was performed under approval by the UNMC IACUC in
AAALAC-certified facilities following NIH guidelines
3.2.7 Immunohistochemistry of rat tissues
To determine cellular distribution of EuCF-DTG nanoparticles in tissues, following the
MRI scan (five days after administration of EuCF-DTG nanoparticles) animals were euthanized for
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collection of tissues. Tissues were fixed in 4% PFA overnight and embedded in paraffin. Tissue
sections (5 µm) were cut and mounted on glass slides. For rats, tissues sections were probed with
rabbit anti-rat polyclonal antibody to ionized calcium binding adaptor molecule-1 (Iba-1) (1:500;
Wako Chemicals, Richmond, VA, USA) to detect macrophages. Primary antibody was detected
with anti-rabbit secondary antibody conjugated to Alexa Fluor 594 (Thermo-Fischer Scientific,
Waltham, MA, USA).
3.2.8 Immunohistochemistry of rhesus macaque tissues
Tissues (spleen and lymph nodes) were perfused with phosphate buffer saline (PBS)
followed by post-fixation with 4% paraformaldehyde (PFA) for 3 days at room temperature then
processed in a automated processor in Shandon Citadel-1000 processor (Thermo scientific) for 18
h with reagents in step-wise manner containing 70, 95 and 100% flex followed by Xylene and
paraffin. Finally tissues were embedded using paraffin blocks for further sectioning. Sections 5μthick were cut from the paraffin blocks, mounted on glass slides and labelled with combination of
rabbit monoclonal antibody to CD68 (Sigma-Aldrich, St. Louis, MO, USA) for macrophages and
mouse monoclonal antibodies to SIV-p27. Primary antibodies were labeled with secondary antimouse and anti-rabbit antibodies conjugated to the fluorescent probes Alexa Fluor® 633 and Alexa
Fluor®594 and nuclei were labeled with 4′,6-diamidino-2-phenylindole (DAPI). Slides were cover
slipped with ProLong Gold anti-fade reagent (Invitrogen, Carlsbad, CA), allowed to dry for 24 h at
room temperature and then stored at −20 °C for future use. Images were captured at wavelengths
encompassing the emission spectra of probes, with a 40X magnification objective. Images were
captured using a Zeiss LSM710 confocal microscope and analyzed with Zen 2011 software (Carl
Zeiss Micro imaging)
3.2.9 Toxicological assessments

79
In vivo toxicity of the EuCF-DTG nanoparticles was determined by serum chemistry and
histological examination. For histological examination, 5 μm sections of paraffin-embedded tissues
were affixed to glass slides and stained with hematoxylin and eosin. Images were captured with a
20X objective using a Nuance EX multispectral imaging system affixed to a Nikon Eclipse E800
microscope (Nikon Instruments, Melville, NY, USA). Histopathological assessment was conducted
in accordance with the guidelines of the Society of Toxicologic Pathology. For serum chemistry
analysis, rat blood samples were collected before and five days after EuCF-DTG nanoparticles
administration. Albumin (ALB), alanine aminotransferase (ALT), total bilirubin (TBIL), phosphate
(PHOS), total protein (TP) and amylase (AMY) were quantitated using a VetScan comprehensive
diagnostic profile disc and a VetScan VS-2 instrument (Abaxis Veterinary Diagnostics, Union City,
CA, USA).

3.3 Results
3.3.1 MRI assessment of EuCF-DTG and FA-EuCF-DTG nanoparticles biodistribution
Theranostic nanoparticle relaxation rates (R2) were measured in both PBS and MDM and
were found to increase linearly with increasing iron concentrations, demonstrating paramagnetism
(Figure 3.1C). The linear regression coefficients of determination (r2) for relaxation rate (R2) vs.
iron content for EuCF-DTG and FA-EuCF-DTG nanoparticles were 0.979 and 0.973 in PBS,
respectively (Figure 3.1C left), and 0.985 for both EuCF-DTG and FA-EuCF-DTG nanoparticles
in cells (Figure 3.1C right). The relaxivities of the EuCF-DTG and FA-EuCF-DTG nanoparticles
were r2 = 564 mM-1 s-1 and r2 = 546 mM-1 s-1 in PBS, and r2 = 876 mM-1 s-1 and r2 = 850 mM-1
s-1 in cells, respectively. In comparison with superparamagnetic iron oxide (SPIO) nanoparticles,
FA-EuCF-DTG nanoparticles showed a log-order of magnitude increase in both sensitivity and
specificity at replicate iron concentrations

[223]. T2*-weighted images of FA-EuCF-DTG

nanoparticles in increasing iron concentrations within PBS phantoms exhibited decreasing signal
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intensities, again showing the paramagnetic properties of the synthesized nanoparticles (Figure
3.1D). Together, these data confirmed magnetic sensitivity.
In vivo assessment of EuCF-DTG and FA-EuCF-DTG nanoparticle biodistribution was
performed in Sprague Dawley rats following either intravenous (IV) or intramuscular (IM)
injection (Figure 3.3A). The experimental timeline for the EuCF-DTG nanoparticle injection and
MRI scanning is shown in Figure 3.2A. MR images representative of pre-injection and 2,5, and 10
days post-injection time points are shown in Figure 3.2B A reduction in T2*-weighted signal
intensity in the MRI images can be seen within animals liver (red highlight) and spleen (green
highlight) at all post-injection time points, reflecting the presence of iron due to nanoparticle
distribution to these tissues.
In vivo assessment of EuCf-DTG nanoparticle biodistribution was also performed in rhesus
macaques infected with simian immunodeficiency virus (SIV). Administration of theranostic
nanoparticles to these animals was proof-of-concept to determine subsequent biodistribution in a
large animal during viral infection, such an animal model is much more comparable to humans
infected with HIV-1. Plasma viral loads ranged from 106-107 copies/mL in the tested animals.
Figure 3.3C shows a schematic of the uptake of EuCF-DTG nanoparticles by macrophages and the
establishment of a reticuloendothelial system drug depot. MR images of rhesus macaques before
nanoparticle injection and 5 days post-injection revealed a significant decrease in T 2-weighted
signal within the liver and the spleen after 5 days (Figure 3.3D). This change in T2 signal intensity
proved to be higher within the liver as compared to the spleen, indicating a possible increase in
uptake of EuCF-DTG nanoparticles within hepatic tissue. Such shortening of T 2 in the rhesus
macaque MR images are comparable to MR images taken of EuCF-DTG at identical timepoints,
suggesting that EuCF-DTG biodistribution is similar between the species.
3.3.2 DTG, iron and cobalt validation tests in both rats in rhesus macaques
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The concentrations of the various components of EuCF-DTG nanoparticles within
administered animals was determined by multiple independent techniques: iron concentration was
estimated in vivo by MRI, DTG drug concentration was determined ex vivo by ultraperformance
liquid chromatography tandem mass spectrometry (UPLC-MS/MS), and cobalt concentration was
determined ex vivo by inductively coupled plasma mass spectrometry (ICP-MS) (Figure 3.6A-C).
Quantification of iron concentrations within the liver and spleen of both rats and rhesus macaques
was performed by MRI T2 mapping, and subsequently compared with respect to time and route of
administration (Figure 3.5A). Iron concentrations were two-fold higher in animals given IV
injections compared to animals given IM injections (Figure 3.5A) IV injected animals displayed
decreasing iron levels in the liver and spleen over time, while corresponding iron levels in IMinjected animals were lower but sustained over the 10-day experimental time course. Comparison
of tissue iron and cobalt levels exhibited a similar trend of DTG drug levels (Figure 3.5A-B).
Figure 3.5C shows liver and spleen DTG concentrations at days 2 and 5. Figure 3.6 D-E illustrates
cobalt and DTG plasma concentrations. Drug levels in liver and spleen were approximately 2-fold
higher at day 2 post-treatment compared to day 5 post-treatment. The DTG levels in liver at day 2
and day 5 were 112±42 ng/g (IV) and 91.2±32 (IM) ng/g versus 47.3±44 ng/g (IV) and 27.12±15
ng/g (IM), respectively; whereas, DTG levels in the spleen at day 2 and day 5 were 39.3±21 ng/g
(IV) and 82.4±41 ng/g (IM) versus 54.8±23.3 ng/g (IV) and 15.12±5.4 ng/g (IM), respectively. In
general, both IV or IM administration of nanoparticles showed coordinate tissue and plasma drug
and cobalt levels. Liver macrophage uptake of nanoparticles was 2.5-fold higher than splenic
uptake of nanoparticles (Figure 3.5A-C). A correlation analysis of iron levels obtained by MRI,
cobalt levels by ICP-MS, and DTG drug levels by UPLC-MS/MS was performed in both the liver
and spleen in IV and IM injected animals to validate the usefulness of MRI to track nanoparticles
in real-time. Figure 3.5F shows Pearson correlation plots between in vivo MRI iron levels and both
tissue DTG and cobalt concentrations. Day 5 iron levels measured by MRI are plotted versus cobalt
levels for individual animals given IM or IV injections are shown in Figure 3.5D. Such plots show
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a strong correlation between iron, cobalt, and DTG concentrations within the liver and spleen, with
Pearson’s correlation coefficients of r = 0.8949 within the liver, r = 0.9396 within the spleen, r =
0.6505 within both liver and spleen for iron versus cobalt, and r = 0.789 within both liver and spleen
for iron versus drug. DTG and iron levels within the liver and spleen were directly related to cobalt
concentrations as measured by ICP-MS (Figure 3.5D). Such data suggests that MRI can be used to
estimate the amount of drug that accumulates within reticuloendothelial tissues by using the known
in vivo MRI signal-to-drug ratio for EuCF-DTG nanoparticles (Figure 3.7)
Investigation of the biodistribution of EuCF-DTG nanoparticles by MRI in rhesus
macaques was performed to confirm whether the data sets observed in the in vivo rat biodistribution
studies could possibly be observed in a species that is much more closely related to humans. Plasma
and tissue DTG and cobalt concentrations were also measured ex vivo. The liver and kidneys of the
rhesus macaques displayed the highest concentrations of cobalt and DTG, with detectable levels
also being observed in the spleen and lymph nodes (Figure 3.8) Very small amounts of drug or
cobalt was detected within the lungs. Such data suggests that macrophages within
reticuloendothelial tissues of macrophages take up EuCF-DTG nanoparticles.
3.3.3 Intracellular macrophage nanoparticle trafficking in rat tissues
Immunohistology and TEM was performed ex vivo on rat tissues to confirm the localization
of nanoparticles within the liver and splenic macrophages. Figure 3.9A shows tissue sections of
liver and spleen from animals sacrificed 5 days post-EuCF-DTG injection (IM and IV). Tissues
were probed with Iba-1 antibody to identify activated macrophages. The yellow/orange color
highlighted by arrows within the merged images is indicative of the co-localization of EuCF-DTG
nanoparticles (green) within the activated macrophages (red). Figure 3.9B shows corresponding
TEM images of liver and spleen sections 5-days post injection of EuCF-DTG nanoparticles. Blacks
dots can be clearly seen within TEM images in both IV- and IM-injected animals and represent the
cellular localization of nanoparticles within macrophages and immune cells in both the liver and
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the spleen. Such immunohistological and TEM data are in strong agreement with in vitro results
listed in the previous chapter and suggests that nanoparticle retention within these tissues persists
for at least 5 days. Parallel immunohistochemistry studies were performed in rhesus macaque
tissues 5-days post IM injection of EuCF-DTG nanoparticles; histological evaluation was
conducted in accordance with the guidelines of the Society of Toxicologic Pathology, and no
anomalies were found other than those that are common in SIV infected animals. Biochemical or
hematological effects of EuCF-DTG nanoparticle administration to rhesus macaques were not
observed.

3.4 Discussion
Synthesized theranostic nanoparticles contain individual functional components that
improve their diagnostic and therapeutic potential. First, the CF component enhances MRI signal
sensitivity and specificity measures [223]. The images show excellent T2 relaxivity. As such, they
can be readily used for ARV biodistribution studies. High relaxivity results in enhanced sensitivity
for ferrite quantification. Second, the nanoparticle’s unique spinel structure permits the
incorporation, in a formed lattice, of rare earth elements. This includes, but is not limited to,
neodymium, Eu3+ and gadolinium [223, 242]. Third, Eu3+ provides magnetic and fluorescence
capabilities. Fourth, the translational potential is realized through the nanoparticle’s
biocompatibility [223]. This is facilitated through the outer “soft” lipid layer of the EuCF-DTG
nanoparticles [214, 243]. Fifth, Eu3+ doped CF can be surface-modified by FA for functionalization
[223]. Sixth, the formed FA-EuCF-DTG nanoparticles are highly stable and as such can be made
for systemic use. Seventh, the FA-EuCF-DTG nanoparticles are hydrophilic with a narrow size
distribution. Each contains a “hard” inner matrix of an organic-inorganic hybrid of EuCF and PCL,
which enables the nanoparticles to be loaded with hydrophobic ARVs and have limited to no
toxicities [214]. Eighth, the nanoparticles unique physicochemical properties facilitate entry into
cells. Indeed, the core is made up of EuCF, PCL and DTG, while the outer lipid layers are formed
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with PC, DSPE-PEG2000 and DOPE. The lipid surrounding the EuCF-DTG core serves to
facilitate rapid uptake by macrophages and as such effectively distribute drug into tissue viral
reservoirs. Ninth, the lipid layer shell over the nanoparticle’s core provides inherent stability and
appropriately sized nanoparticles can be readily made in order to optimize cell and tissue delivery.
Indeed, the EuCF-DTG and FA-EuCF-DTG nanoparticles are homogeneous with relatively narrow
nanoparticle size distribution and retention of drug loading capacities and antiretroviral activity.
Tenth, the nanoparticle’s size and shape are comparable to that of LASER ART being developed
for clinical use [202, 229]. The nanoparticles are remarkably consistent in morphology. Electron
microscopic images indicate that all synthesized nanoparticles display lipid layers outside the
EuCF-DTG or FA-EuCF-DTG core matrix. The latter appears smooth with uniform topography
that is particularly important in reducing systemic adverse events. Eleventh, the uptake of
nanoparticles by macrophages is optimized, as endocytosis is facilitated by spherical or semi-rodshaped nanoparticles [206, 244-246].
Prior reports demonstrated that the FA receptor beta (FR-β), highly expressed on
macrophages, could facilitate nanoparticle cell entry [216, 217, 220]. We have previously
demonstrated significantly higher macrophage uptake of FA-decorated nanoformulations
compared to replicate nanoformulations without decoration [206, 247]. In particular, ARV
nanoparticles that were decorated with FA showed higher atazanavir levels in lymphoid organs
such as the spleen and lymph nodes compared to non-decorated particles. Notably, drug levels
paralleled FR-β staining in both macrophage-rich parafollicular areas of spleen and lymph nodes.
FA targeting of abacavir nanoparticles improved drug and pharmacokinetics and antiretroviral
activity [196]. Moreover, demonstration of human serum albumin nanocapsules that were surface
modified with FA led to macrophage internalization [218]. Formulation uptake was three-fold
higher in FR-β-positive macrophages than in macrophages not expressing FR-β. Similarly, FR-βspecific targeting of methotrexate nanoparticles suppressed inflammation associated with type II
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collagen-induced arthritis models [219]. Furthermore, macrophage targeting of FA-conjugated iron
oxide nanoparticles were described [215] and reflect our own results. In the current report, we
showed higher uptake of FA-EuCF DTG nanoparticles in reticuloendothelial tissues (Figure 3.4,
Figure 3.6). Moreover, we confirmed that FA decorated nanoparticles showed higher macrophage
uptake (Figure 3.4) [206, 247]. Therefore, the macrophage-targeting strategy presented in our study
for FA-mediated uptake of nanoparticles will enable targeting of nanoformulated drug particles.
Nanoparticle migratory behavior was investigated in rodents and non-human primates. MR
images showed decreased signal intensity within the liver and spleen. Corresponding MRI T2
values revealed that iron levels matched the drug PK and biodistribution profiles. Validations were
made by analysis of cobalt and drug content. No significant differences in deviation from linearity
for either drug or cobalt levels were found over time. Co-localization of nanoparticles within
macrophages was seen using confocal and electron microscopy in both cell culture and
histopathological tissue analyses, highlighting the importance of Eu3+ as a fluorescent tag. Assay
of cobalt and iron along with drug content provided MRI confirmation results. Our finding of
preferential macrophage uptake of nanoparticles paralleled the observed PK and biodistribution
results [243-246]. With the successful development of the multi-modal nanoprobes in rhesus
macaques, we posit that macrophage-targeted theranostics can be useful as a testing platform to
assess drug biodistribution in humans. Macrophages loaded with theranostic nanoparticles can
move throughout the body and target tissue sites of residual latent virus [207, 248, 249]. Notably,
the nanoparticles maintain their integrity and ARV efficacy. Most importantly, nanoparticle
distribution can be monitored and tracked in real-time [207, 223]. Overall, our newly-developed
platform provides a means to accurately and effectively optimize the delivery of antiretroviral drugloaded nanoparticles into macrophages.
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In conclusion, the efficacy and structural integrity of the nanoprobe platform was
confirmed in rats and SIV-infected rhesus macaques by MRI. FA-functionalized EuCF-DTG
nanoparticles showed enhanced nanoparticle uptake and antiretroviral activity. EuCF-DTG was
localized to recycling macrophage endosomal compartments without evidence for cytotoxicity.

87

3.5 Figures
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Figure 3.1 MRI relaxometry measurements (c-d) MRI signal enhancement effects of EuCFDTG and FA-EuCF-DTG nanoparticles were determined by calculating nanoparticle relaxivity r2
(mM−1s−1) in both PBS (extracellular) and MDM (intracellular) using a 7T MRI scanner. (C)
Nanoparticle relaxation rates (R2) in both PBS and MDM increased linearly with increasing iron
concentrations. (D) T2-weighted images of EuCF-DTG nanoparticles in PBS demonstrate signal
reduction with increasing concentrations of iron.
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Figure 3.2 Nanoparticle biodistribution tests. (A) Time line of the experimental procedure in
the rats is shown (NP: nanoparticles). (B) Representative T2 maps of rats at 2, 5 and 10 days after
IV or IM administration of 2 mg iron/kg as EuCF-DTG nanoparticles (yellow: lung; red: liver;
green: spleen).
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Figure 3.3. (C) Schematic diagram of macrophage-based biodistribution of EuCF-DTG
nanoparticles in the reticuloendothelial system of rhesus macaques (IM: intramuscular). (D)
Representative T2-weighted images of a macaque at 5 days after IM administration of 2 mg iron/kg
as EuCF-DTG nanoparticles (yellow: lung; red: liver; green: spleen).
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Figure 3.4: FA-EuCF-DTG nanoparticle biodistribution: (A) Schematic diagram of
macrophage-based biodistribution of particles in rats reticuloendothelial system (IV: intra
intravenous). Nanoparticles were administrated in Male Sprague Dawley rats followed by IV or IM
injection and underwent MRI scanning immediately before injection as well as 2 and 5 days postinjection. (B) MR images of rats at day 5 after IM/IV administration of 2 mg iron/kg FA-EuCFDTG particles (yellow: lung; red: liver; green: spleen). (C) MRI T2 mapping again quantified the
iron concentrations in the liver and spleen. Statistical differences were determined using one-way
ANOVA among groups; followed by Student’s t-test. (****p < 0.0001).
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Figure 3.5: Biodistribution of FA-EuCF-DTG nanoparticles in rats. (A) Iron level comparisons
for EuCF-DTG and FA-EuCF-DTG nanoparticle in liver and spleen measured by MRI. (B) Cobalt
concentrations within lymphoid tissues and (C) brain, kidney and lung cobalt levels measured by
ICPMS. (D) Plasma cobalt and (E) DTG concentrations were measured after IV or IM
administration for EuCF-DTG nanoparticles. (F) Pearson’s correlation in liver and spleen tissues
of cobalt levels (determined by ICPMS) in tissues as compared to iron levels determined by MRI
five days after injection of EuCF-DTG nanoparticles (2 mg iron/kg). Statistical differences were
determined using two-way ANOVA among groups. (*p < 0.01; **p < 0.001).

96

97
Figure 3.6 Drug and cobalt concentrations after parenteral EuCF-DTG administration.
Sprague Dawley rats were administered EuCF-DTG nanoparticles (2 mg/kg iron content) by IM or
IV injection on day 0 and sacrificed on days 2, 5 or 10. Plasma was collected for drug analysis on
days 1, 2, 5, and 10 after treatment. DTG and cobalt levels were determined by UPLC-MS/MS and
ICP-MS, respectively, at days 2, 5 and 10. (A) Quantitation of iron in liver and spleen by MRI tests.
(B) Cobalt concentrations. (C) Tissue DTG concentrations. (D) Pearson’s correlation of iron
(determined MRI), cobalt (determined ICP-MS) and DTG (determined UPLC-MS/MS)
concentrations in liver and spleen tissues five days after IV/IM administration of nanoparticles.
Statistical differences were determined using two-way ANOVA among groups; ***p < 0.001;
****p < 0.0001.
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Figure 3.7 Prediction correlations of cobalt and DTG levels in tissues (DTG data sets were
obtained from an independent publication [12]). Cobalt and DTG levels in the tissues were analyzed
by ICP-MS and UPLC-MS/MS. No significant differences in deviation from linearity for either
function (p = 0.6667 and p = 1.0000) were observed. In addition, no significant differences were
observed in the rate of change, by slope measures, in either DTG or cobalt concentrations (p =
0.476). Noted differences in line elevation (p = 0.0011) were linked to the relative concentrations
of each component (cobalt and DTG) administered.

99

100
Figure 3.8: Biodistribution of EuCF-DTG nanoparticles in rhesus macaque tissues and effect
on simian immunodeficiency virus (SIV) RNA loads. (A-C) plasma (results are shown as means
± SEM; n=3) and tissue viral RNA loads of SIV-infected rhesus macaque. (D) Rat and rhesus
macaque T2 relaxation in liver, (E-F) effect of EuCF-DTG treatment on plasma and comparison of
DTG concentrations in post-mortem tissues measured by ICP-MS 5 days post IM injection of
EuCF-DTG nanoparticles and (G-H) cobalt concentrations in the reticuloendothelial organs and
brain regions at 2 mg iron/kg dosage.
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Figure 3.9 Immunohistochemical and morphological localization of EuCF-DTG
nanoparticles. (A) Representative tissue sections of liver and spleen of rats administered EuCFDTG nanoparticles (green) were stained for Iba-1 (red) on activated macrophages. Nanoparticles
were detected in macrophages in both liver and spleen. Arrows in the merged figures indicate colocalization of nanoparticles in macrophages. Images were captured with 63X objective on a Zeiss
LSM 710 confocal microscope. (B) TEM of liver and spleen 5 days after IV or IM injection of
EuCF-DTG nanoparticles (2 mg iron/kg). Panels ii and iii are higher-powered images from regions
indicated by red arrowheads in panel i. Presence of nanoparticles (black dots) is seen in
macrophages in both liver and spleen (panel ii and iii, Figure S11. FA-EuCF-DTG nanoparticles
were seen localization in reticuloendothelial tissues by TEM tests
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CHAPTER 4
Nanoformulated antiretroviral therapy attenuates brain
metabolic oxidative stress
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4.1 Introduction
HIV-1 infection is associated with a spectrum of comorbid conditions that includes the
CNS [250-252]. Nonetheless, many of these conditions have been either reduced or eliminated
following the widespread use of ART. ART has enabled infected people to live nearly normal lives
by reducing plasma and tissue HIV-1 RNA to levels below the limits of detection [7, 174].
Nonetheless, disease morbidities remain, albeit at lower levels, both as a consequence of viral
infection and concomitant illnesses. This includes abuse of illicit drugs, nutritional deficiencies,
neuropsychiatric disorders, and a variety of comorbid infectious diseases that include hepatitis and
opportunistic viral and parasitic infections. Malignancies, depression, and immune dysfunctions
are specifically linked to cognitive and behavioral abnormalities as areARVs themselves. The latter
plays a role in direct neurotoxicity and consequent neuropsychiatric compromise [253, 254].
Among them, to date, efavirenz is known to affect neuronal function [255]. The potential effects
that other ARVs may have on brain function and metabolism remain poorly understood. Such drugassociated toxicities could become more pronounced as commonly used ARVs are transformed
into LASER ART. Such achievements have been made possible by chemical drug modifications
enabling lipophilic hydrophobic nanocrystals to be created that markedly prolong the drug’s
apparent half-life [256, 257]. One of the ARVs, dolutegravir (DTG), has received notable attention
for its potential for transformation into a long-acting drug as well as its potential albeit rare
toxicities [256]. In 2013, DTG was approved by the U.S. Food and Drug Administration and soon
afterwards broadly incorporated in combination ART regimens based on its potency and limited
viral resistance patterns [258-260]. While the drug is generally well tolerated, reports have emerged
that in some aged patients and females, adverse events could signal off-target drug effects involving
the CNS [256]. Given DTG’s key role in HIV-1 therapeutic regimens, studying the intricate
metabolic mechanism of how and why neural effects occur could improve disease outcomes.
Further, as DTG use increases among older patients, the knowledge of who could be at risk and

106
any means to prevent it appears timely. The realization of LASER ART could, in part, facilitate
any untoward drug effects as the circulating drug half-life broadens further. Alternatively,
nanoformulated drug improvements in ARV uptake, retention, and biodistribution into tissues and
organs where free drug may not easily reach could attenuate adverse events by further reducing the
impact of virus on disease events and in control of untoward macrophage inflammatory responses.
Indeed, while LASER ART can significantly improve antiretroviral clinical potency, it requires
high doses to maintain the required four times the effective dose 90 in plasma to elicit sustained
viral restriction [257, 261-266]. With this in mind, we investigated the metabolic effects of free and
nanoformulated DTG in five different anatomical brain regions using untargeted and unbiased
metabolomic detections. DTG was administered intramuscularly at 45-mg/kg doses over a 7-day
time course. This enables up to 100 times the oral therapeutic plasma concentration. Reported
steady-state plasma concentration obtained from HIV-1-infected adults after ten doses of
monotherapy with 50 mg (once daily) DTG tablets is 3.34 μg/mL (Cmax), whereas in the current
study, plasma concentration of injectable DTG for a single free DTG injection was up to 11.29
μg/mL [267, 268]. The frontal cortex (FC), ventral cortex (VC), dorsal cortex (DC), hippocampus
(H), and cerebellum (CR) were dissected and then analyzed using liquid chromatography-mass
spectrometry (LC-MS)- based global metabolomics. The results showed that “high parenteral
doses” of free DTG induced disordered brain metabolism as defined by increases in specific
energy-related metabolites and their pathways all linked to oxidative cellular processes. These were
seen predominantly in the cerebellum and cortex and were attenuated to basal levels by the use of
DTG delivered as a nanoformulation. While higher dosages of DTG could affect neurotoxicities,
any concern in such administration as a long-acting antiretroviral was abrogated by an established
nanoformulated drug delivery system.

4.2 Materials and methods
4.2.1 Preparation and characterization of nanoformulated DTG
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For preparation of P407-DTG, 0.5% (w/v) P407 was mixed with 1% drug. The suspensions
were homogenized at 20,000 psi using an Avestin Emulsiflex C3 homogenizer (Avestin Inc.,
Ottawa, ON, Canada) until the desired particle size (300– 400 nm) was reached. Free polymers and
nonencapsulated drug particles were removed by centrifugation; the nanoparticles were
resuspended in 0.2% P407. Drug loading was determined using reversed-phase high-performance
liquid chromatography (HPLC) and ultra-performance liquid chromatography tandem mass
spectrometry (UPLC-MS/MS) as described. Particle size, polydispersity, and zeta potential for the
nanoformulations were determined by dynamic light scattering using a Malvern Zetasizer NanoZS instrument (Malvern Instruments Inc., Westborough, MA, USA).
4.2.2 DTG injection and brain tissue collection
Both nanoformulated and free DTG with their corresponding controls (vehicle only) were
introduced by intramuscular injections with a loading dose of 45 mg/kg. Animals treated with
nanoformulations were treated once while the free DTG group was treated every other day over a
1-week span (i.e., 4 total injections over 7 days) to maintain drug levels in the animals. Free DTG
was dissolved in a buffer of (v/v) 43% ethanol, 5% cremophor, 20% propylene glycol (propane1,2-diol), and 32% PBS. In the global metabolomics analysis, the same buffer and nanoformulation
without DTG were used as controls. Mice were anesthetized with 1–2% isoflurane in oxygen and
then aligned in a water-jacketed holder for microwave irradiation with a Muromachi Microwave
Fixation System (10-kW model, Muromachi Kikai Co., Ltd., Chuo-ku, Tokyo, Japan). Irradiation
time was 800 ms at 4.9 kW [269]. Single voxel localized spectra were acquired post-mortem at the
midbrain to ensure metabolite level stabilization using point-resolved spectroscopy. Spectra were
acquired with a repetition time of 4 s and echo time of 50 ms, 128 averages, using birdcage coil
transmit, and received on a 7-Tesla/16-cm Bruker Pharmascan (Karlsure, Germany) MRI/MRS
system. Single-scan, localized, unsuppressed water signals were acquired as a reference for
metabolite normalization. Brains with abnormal N-acetylaspartate (NAA) or lactate concentrations
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were eliminated from further analysis. Five animals were selected for further brain dissection and
analysis. All specimens were from the same genetic strain (Balb/cJ), males and similar ages (7
weeks). After spectroscopic validation of microwave irradiation euthanasia, brains were isolated
and initially split into hemispheres, with both hemispheres dissected into subregions. Subregional
dissection followed anatomical boundaries to separate the frontal cortex, ventral cortex, dorsal
cortex, hippocampus, and cerebellum. Following dissection, all tissues were flash frozen in dry ice
and stored at − 80 °C.
4.2.3 Metabolome extraction
Brain tissue subregions were extracted as previously described [270]. Briefly, 0.6 mL of
cold methanol:H2O (4:1, v/v) were added per 10 mg tissue (solvent volume was adjusted
accordingly to tissue weight). Homogenization was performed with glass beads in a homogenizer
and sonicated in an ice bath for 10 min. The mixtures were then transferred to 1.5-mL Eppendorf
vials and rinsed with additional 200 μL extraction solvent. To precipitate proteins, the samples were
incubated for 1 h at − 20 °C, followed by a 15-min centrifugation at 13,000 rpm at 4 °C. The
resulting supernatant was evaporated to dryness in a vacuum concentrator. The dry extracts were
then reconstituted in acetonitrile:H2O (1:1, v/v), normalized by tissue weight, sonicated for 10 min,
and centrifuged for 15 min at 13000 rpm and 4 °C to remove insoluble debris. The supernatants
were transferred to HPLC vials and stored at − 80 °C prior to LC-MS analysis.
4.2.4 HILIC-MS and data analysis
The extracts were analyzed on a 6550 iFunnel QTOF mass spectrometer coupled with a
1290 UPLC system (Agilent Technologies, Santa Clara, CA). For global metabolomics, a Luna
Aminopropyl, 3 μm, 150 mm × 2.0 mm I.D. HILIC column (Phenomenex, Torrance, CA) was used.
The mobile phase was composed of A = 20 mM ammonium acetate and 40 mM ammonium
hydroxide in 5% ACN and B = 95% acetonitrile. A linear gradient from 100% B (0–2 min) to 100%
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A (17–33 min) was applied with a 15-min re-equilibration time. The flow rate and injection volume
were 250 μL/min and 5μL, respectively .ESI source condition swere set as follows: dry gas
temperature, 200 °C; flow, 11 L/min, fragmentor, 380 V; sheath gas temperature, 300 °C; flow, 9
L/min; nozzle voltage, 500 V; and capillary voltage,− 500 Vin ESI-negative mode. The instrument
was set to acquire data over the m/z range 50–1000, with the MS acquisition rate of 1 spectra/s.
The sample sequence was randomized to avoid systematic decreases in signals over sample sets.
For the MS/MS of selected precursors, the default isolation width was set as narrow (∼ 1.3 m/z),
with a MS acquisition rate at 2 spectra/s and MS/MS acquisition at 2 spectra/s to acquire over the
m/z range 50–1000 and 25–1000; respectively. MS/MS data were acquired at the collision energy
of 20 V. LC-MS data were converted to mzXML files using Masshunter Acquisition Software
(Agilent Masshunter 6.0B). The mzXML files were uploaded to XCMS Online web platform for
data processing (https://xcmsonline.scripps. edu) including peak detection, retention time
correction, profile alignment, and isotope annotation [271]. Data were processed using both
pairwise and multigroup comparisons, and the parameter settings were as follows: centWave for
feature detection (Δ m/z = 15 ppm, minimum peak width = 10 s, and maximum peak width = 60
s); obiwarp settings for retention time correction (profStep = 0.5); and parameters for
chromatogram alignment, including mzwid = 0.015, minfrac = 0.5, and bw = 5. The relative
quantification of metabolite features was based on extracted ion chromatogram areas. Paired
parametric t test and one-way ANOVA (post hoc Tukey test) were used to test the variation pattern
of metabolite features between and across cell samples. The result outputs, including EICs,
pairwise/multigroup cloud plot, multidimensional scaling plots, and principle components, were
exported directly from XCMS Online. Generally, the numbers of total pairwise comparison features
and significantly altered features (statistically defined as p value < 0.01, including both upregulated
and downregulated features) were reported in this study.
4.2.5 MDM and neuronal culture assays
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Human monocyte-derived macrophages (MDM) were isolated and then differentiated as
described [227]. MDM were cultured in Dulbeccos Modified Eagle medium (Invitrogen)
supplemented with 2 mM L-glutamine, 100 μg mL−1 streptomycin, 100 U mL−1 penicillin, and
2% fetal calf serum. Murine neurons were isolated from E16-E17 (embryonic) mouse whole brain
tissues. Briefly, embryonic day 16 mice were harvested by cesarean section from anesthetized
pregnant dams (C57BL/6 strain). The animal protocol was approved by the Animal Care and Use
Committee of University of Nebraska Medical Center. Whole brain tissues were isolated and
dissociated by 10% (v/v) trypsin (Life Technologies, Bethesda, MD) digestion and trituration with
a fire-polished Pasteur pipette. Cell culture dishes were coated with 33 μg/mL poly-D-lysine. The
cells were plated in neurobasal medium supplemented with B27, 300 μM glutamine, 25 μM
mercaptoethanol, and streptomycin/amphotericin B (Life Technologies, Waltham, MA). Three
days after plating, 50% of the medium was changed and subsequently the medium was changed
every 6 days. Cells were maintained in the culture for 8–10 days for complete differentiation before
any treatment.
4.2.6 Cell-based DTG measurements
MDM and neuron cells with different treatments were rinsed with phosphate-buffered
saline (PBS) and extracted with acetonitrile:H2O:methanol (2:1:2, v/v/v) using freeze-thaw method
as described elsewhere [270]. The samples were centrifuged at 16,000g at 4 °C for 15 min and the
supernatant was directly injected into the triple-quad 6495 (Agilent Technologies, Santa Clara, CA)
operated in multiple reaction monitoring mode (MRM), where the collision energies and product
ions (MS2 or quantifier and qualifier ion transitions) were pre-optimized (quantifier ion 420 to 295
and qualifier ion 420–277). Cycle time was 150 ms for each transition. ESI source conditions were
set as following: gas temperature 250 °C, gas flow 14 L/min, nebulizer 20 psi, sheath gas 250 °C,
sheath gas flow 11 L/min, capillary voltage 3000 V, nozzle voltage 1500 V, and EMV 1000 V in
ESI-positive mode. The analyses were performed on a Waters UPLC BEH Amide column (50 × 1
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mm, 1.7 μm) (Waters Corporation, Milford. MA). The mobile phase was composed of A = water
with 20 mM ammonium formate and 0.1% formic acid and B = acetonitrile with 0.1% formic acid.
A linear gradient from 5% B (0–0.5 min) to 30% B (0.5– 5 min, maintaining for 2 min) was applied.
Then, the gradient was set to the initial 5% B within the next 1 min. A 2-min reequilibration time
was applied to the column for re-equilibration. The flow rate was 200 μL/min, and the sample
injection volume was 2 μL.
4.2. 7 Reactive oxygen species (ROS) measurements
ROS were measured in neuron and MDM cells with the probe DCFDA (dichlorofluorescin
diacetate, abcam, Cambridge, MA). Cells were seeded on black, clear-bottomed 96-well plates.
After cells were pre-cultured with different treatments, the media were removed and the cells were
washed with 1 × buffer (supplied with the kit). Cells were incubated for 45 min in 1× buffer
containing 25 μM DCFDA at 37 °C. DCF production was measured by fluorescence spectroscopy
with excitation wavelength at 485 nm and emission wavelength at 535 nm. In this study, the cells
were treated with increasing concentrations of free DTG, nano-DTG, and various vehicle, positive,
and negative controls to compare ROS generation and lactate dehydrogenase (LDH)-based
cytotoxicity generated by such treatments. The highest DTG levels measured in the mouse brain is
in the micromolar range so the highest dosing concentration used for ROS experiment was set to
500 μM in the dosing medium, which did not show significant cytotoxicity. TBHP (tert-butyl
hydroperoxide; 10 μM) and PBS were used as the positive and negative controls, respectively. The
vehicle control for nanoformulated DTG was composed of poloxamer micelles without the drug.
The vehicle control for free DTG was composed of 43% ethanol, 5% cremophor, 20% propylene
glycol (propane-1,2-diol), and 32% PBS (v/v). To further validate the protective effect of the P407
nanoformulation in mediating the oxidative stress, we conducted additional experiments to measure
ROS formation in neurons and MDM cells treated with free and nanoformulated DTG with a series
of dilutions from 10 to 100 μM of drug and then challenged with the positive control 10 μM TBHP

112
to induce further oxidative stress. Specifically, cells (both MDM and neurons) were treated for 2 h
with various vehicle or drug concentrations. Then, cells were washed and new media was added,
and after 24-h culture, cells were challenged with TBHP for 2 h, followed by fluorescence-based
ROS measurements.

4.3 Results
4.3.1 Brain region-specific metabolomics after free and nanoformulated DTG injections
Following free and nanoformulated DTG mouse injections, global metabolomics were
performed on five dissected brain subregions including the FC, VC, DC, H, and CR (Figure 4.1).
The effects of free DTG on the brain metabolome were more pronounced within the FC and CR
(Figure 4.2a). In free DTG treated mice, the FC and CR showed the most pronounced metabolite
dysregulations with 130 and 73 features in comparison to 50, 58, and 61 for the VC, DC, and H.
Each of the numbers listed are posted in comparison to controls. The dysregulated metabolites
observed in the CR overlapped, in part, with those observed in the other four brain subregions. In
contrast to the metabolite effects seen by free DTG, nanoformulated DTG-treated animals showed
few dysregulated features. Interestingly, the number of dysregulated features had a narrower range
from 33 to 17, which on average represents a third of the number in the free DTG treatment group.
Furthermore, equivalent DTG drug concentrations were measured in all five brain regions in mice
treated with either free or nanoformulated DTG, demonstrating the advantages of increased
macrophage uptake and retention and apparent plasma drug half-life of the nanoparticle delivered
DTG compared to free drug as a delivery system. Statistical significant differences in DTG
concentrations were only observed in the H, where lower drug concentrations were measured in
the nanoformulated drug-treated mice. However, the fold change (0.63) was valued as small and
unlikely to affect the observed metabolite response differences (Figure 4.2b). Indeed, DTG
nanoparticles are rapidly endocytosed by macrophages and release drug in a controlled manner in
tissue target locations, which more likely reflects the differences seen.
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Among the many dysregulated metabolites seen in brain subregions in the free DTGtreated group, the most affected were identified as energy-related pathways, including glycolysis
and the tricarboxylic acid (TCA) cycle (Figure 4.3). Also, the dysregulation of nicotinamide
adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP), known
cofactors in redox reactions, proved highly relevant due to linkages to oxidative stress related to
xenobiotics and environmental pollutants affecting biological systems. The dysregulation of these
was not observed between controls and DTG nanoparticles, which suggests negligible drug brain
metabolic disruption when DTG was encased in nanoformulations.
4.3.2 DTG and oxidative stress
In addition to energy-related pathways, the most significant change in DTG-induced brain
metabolism was in ascorbic acid and glutathione degradation. These changes are depicted in Figure.
4.4 for both free (a, b) and nanoformulated (c, d) DTG in each brain subregion. These values
represent the ratio of the amount found in the controls divided by the amount found in the treated
mice for ascorbic acid and GSH, as they are depleted with oxidative stress. Conversely, the values
for threonate and GSSG represent the ratio of the amount found in the treated mice divided by the
amount found in their corresponding controls. In these assays, higher ratios reflect greater degrees
of oxidative stress seen as visual darker shades with oxidation, red for depletion of protecting
metabolites (ascorbic acid and GSH) and green for the increase in oxidation
products (threonate and GSSG).
The most substantial changes in ascorbic acid levels were observed in the FC and CR in
animals treated with free DTG. Similarly, increases in threonate further support the presence of
oxidative stress (Figure. 4.4a). Analogous to ascorbic acid and threonate metabolic dysregulation
in free DTG treatment groups, GSH and GSSG showed similar effects with the exception of
increases in oxidative stress seen across each of the five brain regions (Figure. 4.4b). All changes
found in free DTG groups are statistically significant (p value < 0.05) with the exception of ascorbic
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acid levels observed in the H (Figure 4.6). In contrast to free DTG, nanoformulated DTG treated
animals showed less ROS brain-associated metabolic dysregulation. In Figure. 4.4c, d, more limited
changes were seen without statistical significance compared to controls. It should be noted that
similar brain drug levels between free and nanoformulated drugs were seen across both
formulations and as such cannot explain the experimental differences (Figure 4.2b). To investigate
the metabolic source of the oxidative stress and the association with nanoformulation, a number of
mechanistic laboratory experiments were performed for cross validation and extension.
4.3.3 Nanoparticle DTG encasement abrogates brain oxidative stress
In attempts to elucidate any neuroprotective mechanism underlying the DTG
nanoformulations, we employed mouse embryonic neuron cells and human MDM for testing. Each
was treated with free and nanoformulated DTG with the addition of their respective vehicle
controls. ROS formation was measured orthogonally in neurons and MDM using fluorescence
based commercial kits (DCFDA, Figure 4.5a, b, respectively) and administered at 100 and 500 μM.
Values are reported as fold changes compared to respective vehicle controls. Neurons treated with
free but not nanoformulated DTG showed increases in ROS of up to 1.5 times of control. In contrast
for MDM, free and nanoformulated DTG induced more limited ROS effects altering metabolite
concentrations 0.8 and 1.2 times, respectively, when given at 100 μM. The abilities of nanoparticles
to modestly increase ROS suggested that P407 by itself is not an antioxidant but that the protective
mechanism could be more physically linked. ROS levels in free DTG cell cultures were higher than
those in the vehicle controls as aligned with the notion that DTG can itself induce oxidative stress.
More interestingly, comparisons between free and nanoformulated DTG supported the hypothesis
that nanoformulation can reduce oxidative stress and protect neurons (Figure 4.7a–d). In attempts
to sort out these differences and to better elucidate the effects of free and nanoformulated DTG and
relevant drug delivery vehicles on ROS induction, we performed dose-response ROS induction
following oxidative stress induced by TBHP. In these experiments, neuron and MDM cells were

115
treated with both free and nanoformulated DTG (concentration between 10 and 100 μM) followed
by the addition of 10 μM TBHP as an oxidative stress inducer. As shown in Fig. 5c, a clear ROS
response was seen in neurons treated with either free or nanoformulated DTG, while no effect was
seen for vehicle controls. Most importantly, for MDM (Figure. 4.5d), free DTG challenged with
TBHP induced ROS formation in a dose-response at higher concentrations (60 to 100 μM),
reflective of what was observed previously in neurons. In contrast, addition of nanoformulated
DTG to the cultures attenuated the TBHP response signaling control of ROS or the ability to buffer
such effects by the nanoformulations. These latter data provide a mechanism for how the
nanoformulation could control ROS production in specific brain regions. Finally, we measured
cellular uptake of free and nanoformulated DTG at 1, 10, and 100 μM (Figure 4.5e, f) in attempts
to better uncover mechanisms. As shown in Figure 4.5e, the concentrations of nanoformulated DTG
in neurons were almost one order of magnitude higher than those in the free DTG drug. However,
for MDM, the concentration was similar between two forms of DTG treatment (Figure 4. 5f), which
could be explained by different drug uptake mechanisms, biotransformations, and cell metabolic
capacity between both cell types. However, considering the fact that DTG concentrations of nanoDTG-treated cells are one order of magnitude higher than those of free DTG-treated cells at the
same dosing concentration (Figure 4. 5a, b), the nanoformulations shows its protective effect in
modulating ROS level (e.g., fold change of 4 at 100 μM for free DTG and fold change of 1.2 at 10
μM for nano-DTG). As for MDM cells (Fig. 4.5f), the free DTG drug challenged with TBHP
induced ROS formation with a clear concentration-response at higher concentrations (60 to 100
μM), similar to neurons. This explains, in part, the unexpected increase in ROS production during
initial TBHP challenge in neurons (Figure 4.5c).

4.4 Discussion
The possible link between ART and neurotoxicities has only been postulated. Here, we
investigated for the first time the effect of DTG on global metabolome during administration of
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free and nanoformulated drugs. The results showed that while free DTG delivered at high doses
can affect the brain metabolism for oxidative stress, the effects can be curtailed by how the drug is
formulated. Altogether, our results affirm that if and when DTG is used in part of a LASER ART
regimen, it can be administered safely. It is acknowledged and despite restricted viral growth by
cART, up to 60% of HIV-1- infected patients show HAND-related cognitive and behavioral
abnormalities induced by comorbid infectious, cancerous, metabolic, and neuropsychiatric events
[175]. ARVs themselves are potential contributors and most can elicit varying degrees of
neurotoxic reactions. Each of these “purported” adverse effects is independent of drug class that
includes nucleoside reverse transcriptase inhibitors (NRTIs, e.g., abacavir and lamivudine), nonNRTIs (e.g., efavirenz), entry inhibitors (e.g., maraviroc), inhibitors of the viral protease (e.g.,
atazanavir), and integrase inhibitors (INSTI, e.g., DTG). Notwithstanding, each of the drugs has
revolutionized patient care and has improved longevity and disease morbidities considerably, and
to the degree, HIV-1/AIDS is now a treatable chronic, managed disease. DTG, in particular, is used
commonly in both first- and second-line therapies that have been projected by 2019 to account for
37% of the adult first-line NNRTI/INSTI market, representing 3.8 million patients [272]. Compared
to NRTIs, DTG is durable and can cross the BBB allowing it to easily achieve therapeutic brain
concentrations [273]. However, side effects of DTG are reported and include insomnia and
headache as well as more significant allergic reactions and abnormal liver function in dual hepatitis
virus-infected people [259]. Low concentrations of DTG can trigger suicidal death in erythrocytes
characterized by cell shrinkage and membrane scrambling with phosphatidylserine translocation to
the erythrocyte surface [274]. Putative neuropsychiatric effects were reported in adult patients who
received DTG, raltegravir, and elvitegravir, suggesting specific toxicities linked to integrase strand
transfer inhibitors [253, 256, 275-279]. Nonetheless, others have debunked such results with a sole
substantiated DTG metabolic effect being a rise in serum creatinine due to tubular secretion
inhibitions [280, 281].
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Oxidative stress plays a principal role in the pathogenesis of neurodegenerative disorders
including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and HIV-1
associated dementia [282]. A spectrum of xenobiotics, mitochondrial dysfunction, accumulation of
aberrant misfolded proteins, inflammation, and defects in protein clearance are all known to
accumulate ROS. Xenobiotics can be oxidized to free radicals by cytochrome P450 and generate
ROS following the quenching of the radicals. DTG has been shown to be oxidized by CYP3A4,
even though the major metabolic reaction was glucuronidation of DTG principally by metabolic
reaction was glucuronidation of DTG principally (in humans) [283]. Dysregulation of glycolysis,
TCA cycle, and redox cofactors could indicate a need of cells engaging in neutralizing ROS
processes. Another ART drug, efavirenz, was also reported to alter mitochondrial respiration and
enhance ROS generation, resulting in CNS damage [255, 284-286]. Therefore, the need for novel
therapeutic strategies that attenuate neuroinflammation and protect neurons against oxidative stress
is immediate for DTG. Despite the higher DTG dose used in this study over those administered to
HIV-1 infected patients the drug concentrations in brain were equivalent (Figure 4.2b). Of interest
no significant oxidative stress increase was observed during nanoformulated DTG treatment
compared to free DTG-injected mice. Thus, it is speculated that P407 nanoformulation could play
a vital role in mediating ROS formation. Several other non-ionic surfactants including polyethylene
glycol (PEG) and poloxamer 188 have shown protective effects from oxidative damage in both
laboratory and animal models of human disease [287-290]. For example, using a guinea pig spinal
cord injury model, it has been shown that PEG could significantly decrease injury-induced ROS
elevation and lipid peroxidation levels [286]. A further investigation showed that PEG is not an
effective free radical scavenger nor does it have the ability to suppress xanthine oxidase, a key
enzyme in generating superoxide, but can significantly accelerate and enhance the healing process
to restore membrane integrity [289].
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Our in vitro study suggested that surfactant poloxamer-407 could decrease the oxidative
stress and cell damage. Thus, it is very likely that P407 has a beneficial effect on the drug efficacy
of DTG treatment besides its role as a drug delivery system. This protective effect of non-ionic
surfactant nanoformulations could have significant implications on future drug discovery, given
the fact that oxidative stress is one of the most common side effects of many therapeutic drugs.
Induction of oxidative stress can lead to drug failure in clinical trials or phase-out in the market in
later use. Though oral ingestion of antioxidants could deem effective in counteracting such toxicity,
it is not an ideal therapeutic solution due to their side effects or interactions with other medications
or supplements [291-293]. Interestingly, the nanoformulated non-ionic surfactant tested in this
study did not show any obvious toxicity in affecting brain metabolism. Previous studies have also
found that nanoparticles can penetrate the BBB possibly via receptor-mediated endocytosis in brain
capillary endothelial cells [294]. This suggests that another advantage of nanoformulations in
antagonizing oxidative stress is the colocalization of nanoparticles and drug during distribution,
resulting in possible in situ restoration of normal physiological conditions. Further investigation on
the optimization of the material type, size, and formulation as well as its potential application for
generic drug modification is needed. It is worth noting that oxidative stress and malformations in
embryonic developmental including those linked to neural tube defects could occur [295-299].
Future works are certainly required to see if such relationships could occur between DTG and
maternal fetal abnormalities.
In conclusion, we examined DTG brain metabolic activities using mass spectrometrybased metabolite profiling and observed significant dysregulation in energy and oxidative stress
pathways; most notably, glutathione and ascorbic acid were depleted. This effect was significantly
attenuated when DTG was administered as a nanoformulation. This data provides a possible
pathway for the advantages of nanoformulations or other relevant therapeutic drug delivery systems
to preclude systemic toxic reactions and most notably those that involve the nervous system.
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4.5 Figures

Figure 4.1 Workflow of mouse brain global metabolomics study. Free and nanoformulated DTG
with drug administered every other day for three total injections or by a single bolus of 45 mg/kg,
respectively. All mice were sacrificed after 1 week following treatment. After heat fixation by
microwave irradiation euthanasia, brain hemispheres were dissected into subregions including the
FC, the VC, the DC, the H, and the CR. Brain subregions were extracted for untargeted LC-MS
metabolic profiling (mice specimens = 5, total 50 sub-samples)
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Figure 4.2 Total number of dysregulated features among the FC, VC, DC, H, and CR. All the
features were manually filtered. b DTG concentration in brain regions for free and nanoformulated
DTG (nano-DTG) (error represents SEM and “*” represents p value < 0.05). For each experiment,
a minimum of four experimental replicates were used

122

Figure 4.3 Glycolysis/TCA pathways and redox partners with identified metabolites. Fold
change between free DTG and the corresponding control. Those values in circles had a p value <
0.05. All the metabolites were identified using METLIN MS/MS fragment match and confirmed
with their pure standards
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Figure 4.4-Fold change of metabolites indicative of oxidative stress in five different brain
regions. Both free DTG and nanoformulated DTG treatments with their corresponding controls.
Ascorbic acid is oxidized to threonate and GSH is oxidized to GSSG. The color scheme was
selected to show oxidation with darker shades of red for ascorbic acid and GSH and green for
threonate and GSSG. a Ascorbic acid and threonate fold changes for free DTG treatment. b GSH
and GSSG fold changes for free DTG treatment. c Ascorbic acid and threonate fold changes for
nanoformulated DTG treatment. d GSH and GSSG fold changes for nanoformulated DTG
treatment (n = 10 samples from 5 mice). All fold changes in a and b except for H in a have p values
< 0.05. None were found to be statistically significant in c and d. The experiments listed represent
a minimum of four replicates for each group
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Figure 4.5 ROS formation and drug uptake of free and nanoformulated DTG in neurons and
MDM cultures. a, b ROS fold change of neurons and MDM relative to their respective controls,
respectively (error represent SEMand “*” represents p value < 0.01). c, d ROS levels after TBHP
challenge in the neurons and MDM treated with free DTG, nanoformulated DTG, and their
respective vehicle controls with a series of dilution from 10 to 100 μM. The data was normalized
with TBHP-positive control (10 μM). e, f DTG concentration in neurons and MDM respectively
treated with free DTG and nanoformulated DTG. The DTG concentration in neurons treated with
100 μM free DTG equals the DTG concentration treated with 10 μM nanoformulated DTG (dotted
line, 168 ng/106 cells). This comparison by cellular uptake is indicated by the dotted line in c
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Figure 4.6. Relative abundance of oxidative stress biomarkers. (a) ascorbic acid; (b) threonate;
(c) glutathione (GSH); (d) GSH/GSSG ratio in five dissected regions, frontal cortex, ventral cortex,
dorsal cortex, hippocampus and cerebellum (n=10 samples from 5 mice) from mice treated with
free DTG and Nano-DTG compared with their respective controls. All data corresponds to global
metabolomics analysis. Error bars represents standard error of the mean. “*” and “**” represents p
values <0.05, and <0.01; respectively.
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Figure 4.7. Free DTG and nanoformualted
DTG (Nano-DTG) reactive oxygen species (ROS)
formation in murine neurons and human monocyte derived macrophage (MDM) cells 24
hours post treatment. (a) Neurons and (b) MDM treated with 10 µM TBHP (positive control),
free DTG (100 and 500 µM), Nano-DTG (100 and 500 µM), and their respective vehicle controls.
Error bars represent standard error of the mean (n=6).
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CHAPTER 5
Summary and Conclusion, Limitations, and Future
Directions
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5.1 Summary and conclusions
The successful development of combination antiretroviral therapy for the treatment of
HIV-1 undoubtably changed the course of human history, as millions of infected people can now
anticipate a prolonged lifespan instead of a certain and painful death. However, the persistence of
virus and the continued strain of the pandemic on global healthcare has resulted in HIV-1 research
to develop novel strategies to improve upon current antiretroviral therapy. Improvements in
pharmacodynamic and pharmacokinetic profiles have shown remarkable promise in increasing
drug adherence, reducing secondary toxicities, and preventing new infections. Our lab has shown
that the enhancement of the hydrophobicity of current ARVs via nanocrystals incased in
biodegradable polymers allows for the establishment of drug depots within monocytemacrophages,

significantly

prolonging

drug

half-life.

But

experimentation

of

such

nanoformulations within animal models has proved cumbersome, with biodistribution
measurements extending weeks or even months proving particularly tedious.
The first study (chapters 2 and 3) assessed the use of our theranostic nanoparticle platform
and its ability to accumulate within monocyte-macrophages as well as reticuloendothelial tissues.
Theranostic nanotechnology has allowed the rapid screening of drug tissue biodistribution and
pharmacokinetics which allows for pharmacodynamic improvements. Our theranostic nanoparticle
platform was developed with careful consideration of components that allowed assessment of
particle presence as well as component concentration within cells and tissues in vitro, in vivo, and
ex vivo. Encasement of hydrophobic ARVs and imaging contrast agents within a single
nanoformulation produced theranostic nanoparticles with a multitude of modalities, allowing for
validations of the multiple measurements performed. Incorporation of Eu3+ into the nanoparticles
allowed for confirmation of particle presence within cells and tissues via fluorescence confocal
imaging. Cobalt ferrite provided a paramagnetic material necessary for T 2 contrast in MR imaging.
Altogether, our theranostic nanoparticle platform allowed for real time assessment of ARV
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biodistribution and activity that would otherwise not be possible with traditional plasma postmortem tissue concentration analysis.

Upon synthesis, EuCF-DTG nanoparticles showed

remarkably consistent size, size, magnetism, fluorescence, and proper ARV drug loading as well
as drug release in PBS. Administration of EuCF-DTG to in vitro macrophage cell culture resulted
in consistent cellular uptake of nanoparticles, with FA targeted EuCF-DTG showing significantly
higher uptake. Uptake of EuCF-DTG nanoparticles did not affect cellular viability in these studies.
Furthermore, confocal microscopy of in vitro macrophages displayed EuCF-DTG nanoparticles
localizing within subcellular components, with a high proportion of nanoparticles residing within
recycling endosomes. Perhaps most importantly, EuCF-DTG nanoparticles exhibited antiretroviral
activity upon administration to HIV-1 infected in vitro cellular cultures, confirming the therapeutic
effects of our theranostic nanoparticle platform. Real time in vivo MR imaging of rats administered
EuCF-DTG nanoparticles both via IV and IM injection confirmed nanoparticle presence within
reticuloendothelial tissues at 2, 5, and 10 days post-injection. Quantification of iron concentrations
within liver and spleen was performed by MRI T2 mapping with IV injected animals exhibiting a
two-fold increase in iron compared to IM injected animals. Post-mortem tissue concentrations of
cobalt and DTG were measured by ICP-MS and UPLC- MS/MS, respectively. DTG and cobalt
levels following IM or IV injection of nanoparticles showed coordinate tissue and plasm drug and
cobalt levels. Furthermore, MRI iron concentrations performed in vivo were validated by ex vivo
concentrations of cobalt and DTG. Overall, such data suggests that the amount of drug that
accumulates in tissues can be estimated in real time by in vivo MRI by using the known signal-todrug ratio of EuCF-DTG nanoparticles. Post-mortem tissue confocal microscopy confirmed the
presence of EuCF-DTG nanoparticle within recycling endosomal compartments in macrophages,
mirroring results found in in vitro confocal microscopy studies. Additional biodistribution studies
were performed by EuCF-DTG administration to rhesus macaques. Highest concentrations of DTG
and cobalt were found in the liver and kidneys, with detectable levels observed in the spleen and
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lymph nodes. These results suggest that EuCF-DTG nanoparticles are taken up by macrophages in
reticuloendothelial tissues in rhesus macaques, similar to biodistribution studies performed in rats.
Our second study (chapter 4) assessed the possibility that native ARV drug administration
could cause neurotoxicity and whether administration of ARV drug as a nanoformulation could
attenuate any observable neurotoxic effect. While ART restricts HIV-1 replication and
subsequently improves the quality and longevity of life for infected people, such treatment can lead
to adverse clinical outcomes such as drug resistance and systemic adverse events. Both could be
affected by long-acting slow effect release ART. Indeed, maintenance of sustained plasma drug
levels, for weeks or months, after a single-high level dosing, could improve regimen adherence but
additionally affect systemic toxicities, including those of the CNS. To address this a potent and
durable HIV-1 integrase inhibitor used effectively in combination ART was tested. Rodents were
administered parenteral 45-mg/kg doses. DTG-associated changes in CNS homeostasis were
assessed by measuring brain metabolic activities. After antiretroviral treatment, brain subregions
were dissected and screened by mass spectrometry-based metabolomics. Metabolic drug-related
dysregulation of energy and oxidative stress were readily observed within the cerebellum and
frontal cortex following native drug administrations. Each was associated with alterations in neural
homeostasis and depleted canonical oxidation protection pools that included glutathione and
ascorbic acid. Surprisingly, the oxidative stress-related metabolites were completely attenuated
when DTG was administered as nanoformulations. These data demonstrate the importance of
formulation design in control of DTG or perhaps other antiretroviral drug-associated CNS events.
Overall, the data presented in this thesis will have significant impact on research striving
for both the care for HIV-1 patients and the eradication of the virus. A theranostic nanoparticle
platform was designed specifically for HIV-1 therapeutic innovation, allowing for improvements
in pharmacokinetic and biodistribution profiles of LASER ART technology within a relatively
short time frame. Such theranostic technology, to the authors knowledge, is the first such platform
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that has been applied for HIV-1 research. Furthermore, investigation of possible off target
neurological effects of relatively new ARV medications allows for improvements in patient care.
The attenuation of the observed changes in the neuro-metabolome by nanoformulated ARV is
representative of such improvements. Such nanoformulated ARV not only has a longer half-life
and improved biodistribution, but it’s slower systemic release can possibly prevent neurological
side-effects of the drug. Both projects have potential for dramatic influence on future directions of
HIV research.
5.2 Limitations
While the HIV-1 theranostic technology that was developed and experimentally tested
ultimately met our goals that are outlined within this thesis, several limitations of such
nanotechnology exist. Future development and utilization of HIV-1 theranostic nanotechnology
must take note of such limitations and make efforts to overcome them.
A major limitation of our EuCF-DTG theranostic nanoparticle platform was that of drug
loading. Indeed, the ability to load adequate amounts of drug into a nanoscale system while still
containing the necessary contrast agents and fluorescent components is particularly challenging.
EuCF-DTG nanoparticles exhibited a drug loading percentage of ~6.2% weight/weight; while such
concentrations were adequate to exhibit antiretroviral activity in vitro, it is unlikely that such drug
levels would have much of a therapeutic effect on HIV-1 replication in vivo. Specifically,
biodistribution studies of EuCF-DTG nanoparticles performed on SIV-1 infected rhesus macaques
confirmed this issue. While the presence of the nanoparticle component cobalt and the ARV DTG
were confirmed within the plasma and multiple tissue sites, SIV-1 viremia within these same tissues
did not show any differences between pre and post injection of EuCF-DTG nanoparticles. Such
data exhibits that EuCF-DTG being delivered to tissue sites of viral replication and that DTG is
being released, but that DTG levels are not adequate to reduce SIV-1 viremia. Diagnostic
limitations of our EuCF-DTG theranostic nanoparticle platform was the use of MRI as the major
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imaging modality. While MRI is a powerful diagnostic tool with superior spatial resolution, it has
difficulty imaging particular tissues that are relevant to HIV-1 pathology. Specifically, T2 weighted
MR images of tissues or organs containing air, such as the lungs or gastrointestinal tract, cannot be
performed to very low signal-to-noise ratios in such areas. This is a major limitation due to the gut
associated lymphoid tract being a significant HIV-1 reservoir, in which theranostic nanoparticle
deliverance and subsequent MR imaging would be beneficial. Furthermore, MRI has difficulty
differentiating small lymphoid tissues, such as lymph nodes, from the surrounding tissues. The
inability to image and quantify theranostic nanoparticle concentrations within such tissues is a
major limitation.
Metabolomic analysis of the brains of native DTG and nanoformulated DTG administered
mice are limited as it is difficult to ascertain whether metabolic changes in redox metabolites is
truly indicative of HIV-1 associated neurocognitive disorders. Indeed, while the changes that were
exhibited can be classified as neurotoxic, alterations in neuronal homeostasis and depletions of
canonical oxidation protection pools might not result in the manifestation of neuropsychiatric
events. This is characteristic of the majority of psychiatric or neurological studies that utilize animal
models; presentation of adverse behaviors or psychiatric abnormalities is often nuanced and
requires complex questioning between the patient and clinician. Such psychiatric evaluation is not
possible in animals. Deviation from normal baseline behavior, or abnormalities in post-mortem
tissue analysis in comparison to control animals are the only way to establish possible adverse
neuropsychiatric events. The animals utilized in our second study (chapter 4) did not display any
abnormal behaviors during their administration of native or nanoformulated DTG.
5.3 Future Directions
Potential future applications of HIV-1 theranostic technology are both diverse and exciting.
Successful establishment of a theranostic nanoparticle platform allows for rapid assessment of
biodistribution and pharmacokinetics, allowing for newer and more advanced drug delivery and
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targeting schemes for HIV-1 eradication to be evaluated more efficiently. Experimentation that
would take months or years with traditional pharmacokinetic evaluations can be performed within
weeks using a theranostic platform, allowing more time and resources to be put towards more
innovative nanotechnological developments. Additionally, further refinement of theranostic
nanoparticles is a future possibility. Addition of a radionucleotide into the nanoparticle system
allows for another imaging modality; such a theranostic platform would allow for MRI,
fluorescence, and PET/SPECT imaging. Radio-imaging of nanoparticles allows for biodistribution
analysis within tissues that are not possible with MRI. Alterations in nanoparticle components and
size could lead to specific targeting of other HIV-1 reservoirs, such as the brain or lymphoid
systems. Furthermore, magnetic movement of magnetically sensitive nanoparticles into areas of
interest via external magnetic gradients could have significant potential in drug delivery
technology, both in HIV-1 and other diseases. All future directions give optimism to the eventual
eradication of HIV-1 from society.
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